+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Get PDF Full Texts from EurekaMag Chapter 55241

Chapter 55241 provides scholary research titles of which PDF Full Texts are available through EurekaMag.





Hennis, A.J.M.; Hambleton, I.R.; Wu, S-Yuh.; Skeete, D.H-A.; Nemesure, B.; Leske, M.Cristina., 2011:
Prostate cancer incidence and mortality in barbados, west indies

Obertova, Z.; Brown, C.; Holmes, M.; Lawrenson, R., 2012:
Prostate cancer incidence and mortality in rural men--a systematic review of the literature

Ondrusova, M.; Muzik, J.; Kliment, J.; Gulis, G.; Ondrus, D., 2011:
Prostate cancer incidence and mortality in selected countries of Central Europe

Bray, F.; Lortet-Tieulent, J.; Ferlay, J.; Forman, D.; Auvinen, A., 2011:
Prostate cancer incidence and mortality trends in 37 European countries: an overview

Cózar, Jé.M.; Miñana, B.; Gómez-Veiga, F.; Rodríguez-Antolín, A.; Villavicencio, H.; Cantalapiedra, A.; Pedrosa, E.; Dacal, J.Andrés.González.; González, V.Baena.; Jiménez, P.Morales.; Redorta, J.Palou.; Urzáiz, M.Unda.; Asensio, A.Alcaraz.; Ciudin, A.; Jabaloyas, Jé.M.Martínez.; Cortés, C.Ferrandis.; Romero, F.Javier.; Ríos, J.Subirá.; Uría, Jé.Gabriel.Valdivia.; Encinas, J.José.Lobato.; Navarro, Jús.Jiménez.; Llorca, Lís.Pérez.; Vidal, E.Marqués.; Escudero, Jín.Ulises., 2013:
Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010

Marcus, J.L.; Chao, C.R.; Leyden, W.A.; Xu, L.; Klein, D.B.; Horberg, M.A.; Towner, W.J.; Quesenberry, C.P.; Abrams, D.I.; Van Den Eeden, S.K.; Silverberg, M.J., 2014:
Prostate cancer incidence and prostate-specific antigen testing among HIV-positive and HIV-negative men

Loke, T.W.; Seyfi, D.; Sevfi, D.; Khadra, M., 2011:
Prostate cancer incidence in Australia correlates inversely with solar radiation

Aiken, W.D., 2012:
Prostate cancer incidence in Jamaica before and after the introduction of prostate-specific antigen

Zorlu, F.; Zorlu, R.; Divrik, R.Taner.; Eser, S.; Yorukoglu, K., 2015:
Prostate cancer incidence in Turkey: an epidemiological study

Rogers, D.; Boyd, D.D.; Fox, E.E.; Cooper, S.; Goldhagen, M.; Shen, Y.; Del Junco, D.J., 2011:
Prostate cancer incidence in U.S. Air Force aviators compared with non-aviators

Gooren, L.; Morgentaler, A., 2015:
Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens

Pignot, Géraldine.; Salomon, L.; Lebacle, Cédric.; Neuzillet, Y.; Lunardi, P.; Rischmann, P.; Zerbib, M.; Champy, C.; Roupret, M.; Peyronnet, B.; Verhoest, G.; Murez, T.; Quintens, H.; Larré, Séphane.; Houédé, N.; Compérat, E.; Soulié, M.; Pfister, C., 2015:
Prostate cancer incidence on cystoprostatectomy specimens is directly linked to age: results from a multicentre study

Crocetti, E.; Ciatto, S.; Buzzoni, C.; Zappa, M., 2010:
Prostate cancer incidence rates have started to decrease in central Italy

Chu, L.W.; Ritchey, J.; Devesa, S.S.; Quraishi, S.M.; Zhang, H.; Hsing, A.W., 2011:
Prostate cancer incidence rates in Africa

Larrañaga, N.; Galceran, J.; Ardanaz, E.; Franch, P.; Navarro, C.; Sánchez, M.J.; Pastor-Barriuso, R.; Martos, C.; Rodríguez, L.; Vilardell, L.; Chico, M.; Mateos, A.; Fernández, D.; Linares, C., 2011:
Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality

Møller, H.; Roswall, N.; Van Hemelrijck, M.; Larsen, S.Benzon.; Cuzick, J.; Holmberg, L.; Overvad, K.; Tjønneland, A., 2015:
Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark

Bantis, A.; Vasiliou, O., 2009:
Prostate cancer incidence, mortality, total and free prostate specific antigen

Jack, R.H.; Davies, E.A.; Møller, H., 2010:
Prostate cancer incidence, stage at diagnosis, treatment and survival in ethnic groups in South-East England

Josefsson, A.; Adamo, H.; Hammarsten, P.; Granfors, T.; Stattin, Pär.; Egevad, L.; Laurent, A.Engström.; Wikström, P.; Bergh, A., 2012:
Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome

Bjerke, G.A.; Pietrzak, K.; Melhuish, T.A.; Frierson, H.F.; Paschal, B.M.; Wotton, D., 2014:
Prostate cancer induced by loss of Apc is restrained by TGFβ signaling

Dai, J.; Hall, C.L.; Escara-Wilke, J.; Mizokami, A.; Keller, J.M.; Keller, E.T., 2008:
Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

Anonymous, 2008:
Prostate cancer initiatives

Guo, C.C.; Pisters, L.L.; Troncoso, P., 2010:
Prostate cancer invading the rectum: a clinicopathological study of 18 cases

Pendleton, J.; Hopkins, C.; Anai, S.; Nakamura, K.; Chang, M.; Grissett, A.; Rosser, C.J., 2008:
Prostate cancer knowledge and screening attitudes of inner-city men

Darlix, J-Luc.; Sitbon, M., 2007:
Prostate cancer leads to the discovery of a new human infectious retrovirus

Ebelt, K.; Babaryka, G.; Frankenberger, B.; Stief, C.G.; Eisenmenger, W.; Kirchner, T.; Schendel, D.J.; Noessner, E., 2009:
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters

Mischi, M.; Saidov, T.; Kompatsiari, K.; Engelbrecht, M.R.W.; Breeuwer, M.; Wijkstra, H., 2015:
Prostate cancer localization by novel magnetic resonance dispersion imaging

Rosenkrantz, A.B.; Kim, S.; Lim, R.P.; Hindman, N.; Deng, F-Ming.; Babb, J.S.; Taneja, S.S., 2014:
Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales

Artan, Y.; Yetik, I.Samil., 2014:
Prostate cancer localization using multiparametric MRI based on semi-supervised techniques with automated seed initialization

Artan, Y.; Haider, M.A.; Langer, D.L.; van der Kwast, T.H.; Evans, A.J.; Yang, Y.; Wernick, M.N.; Trachtenberg, J.; Yetik, I.Samil., 2010:
Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields

Fradet, V.; Kurhanewicz, J.; Cowan, J.E.; Karl, A.; Coakley, F.V.; Shinohara, K.; Carroll, P.R., 2010:
Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging

Jegu, J.; Tretarre, B.; Velten, M.; Guizard, A-V.; Danzon, A.; Buemi, A.; Colonna, M.; Kadi-Hanifi, A-M.; Ganry, O.; Molinie, F.; Bara, S.; Rebillard, X.; Grosclaude, P., 2010:
Prostate cancer management and factors associated with radical prostatectomy in France in 2001

Levine, R.A.; Priest, S., 2011:
Prostate cancer masquerading as a rectal tumor: a tricky diagnosis

Jakobsen, J.Kristian.; Zakharia, E.Raja.; Boysen, A.Kindberg.; Andersen, H.; Schlesinger, F.Emanuel.; Lund, L., 2014 :
Prostate cancer may trigger paraneoplastic limbic encephalitis: a case report and a review of the literature

McLean, M.A.; Barrett, T.; Gnanapragasam, V.J.; Priest, A.N.; Joubert, I.; Lomas, D.J.; Neal, D.E.; Griffiths, J.R.; Sala, E., 2011:
Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla

Bi, X.; Sterling, J.A.; Merkel, A.R.; Perrien, D.S.; Nyman, J.S.; Mahadevan-Jansen, A., 2014:
Prostate cancer metastases alter bone mineral and matrix composition independent of effects on bone architecture in mice--a quantitative study using microCT and Raman spectroscopy

Conti, G.; L.T.rre, G.; Cicalese, V.; Micheletti, G.; Ludovico, M.Giuseppe.; Vestita, G.Donato.; Cottonaro, G.; Introini, C.; Cecchi, M., 2008:
Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features

Nguyen, B.D., 2007:
Prostate cancer metastases to shoulder arthroplasty: bone scintigraphy

Lee, D.K., 2008:
Prostate cancer metastases to the leg, ankle, and foot

Abbas, T.O.; Al-Naimi, A.R.; Yakoob, R.A.; Al-Bozom, I.A.; Alobaidly, A.M., 2011:
Prostate cancer metastases to the rectum: a case report

Sato, T.; Ishikawa, K.; Paparella, M.M., 2010:
Prostate cancer metastasis to facial nerve

Parkins, G.E.; Klufio, G.O., 2010:
Prostate cancer metastasis to the mandible: case report

Hong, K.Pyo.; Lee, S.Ju.; Hong, G.Sik.; Yoon, H.; Shim, B.Suk., 2010:
Prostate cancer metastasis to the stomach

Mehrzad, R.; Agarwal, A.; Faller, G.T.; Fiore, J.A., 2015:
Prostate cancer metastasis to the stomach: 9 years after the initial diagnosis--case report and a literature review

Chiang, Y.Ting.; Gout, P.W.; Collins, C.C.; Wang, Y., 2015:
Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification

Shrivastava, V.; Christensen, R.; Poggi, M.M., 2007:
Prostate cancer metastatic to the external auditory canals

Katime, E.E.; Khurana, J.S.; Arosarena, O.A., 2013:
Prostate cancer metastatic to the larynx: a case report

Wang, W.; Stroehlein, J.R.; Landon, G.; Ross, W.A., 2014:
Prostate cancer metastatic to the pancreas

Talwar, M.; Self, S.E.; Ullian, M.E., 2013:
Prostate cancer metastatic to the peritoneum in a peritoneal dialysis patient

Jani, A.B.; Johnstone, P.A.S.; Liauw, S.L.; Master, V.A.; Rossi, P.J., 2010:
Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis

Dumache, R.; Puiu, M.; Motoc, M.; Vernic, C.; Dumitrascu, V., 2014:
Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis

Xia, J.; Trock, B.J.; Cooperberg, M.R.; Gulati, R.; Zeliadt, S.B.; Gore, J.L.; Lin, D.W.; Carroll, P.R.; Carter, H.Ballentine.; Etzioni, R., 2013:
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy

Tseng, C-Hsiao., 2011:
Prostate cancer mortality in Taiwanese men: increasing age-standardized trend in general population and increased risk in diabetic men

Stattin, Pär.; Carlsson, S.; Holmström, B.; Vickers, A.; Hugosson, J.; Lilja, H.; Jonsson, Håkan., 2014:
Prostate cancer mortality in areas with high and low prostate cancer incidence

van Leeuwen, P.J.; Connolly, D.; Gavin, A.; Roobol, M.J.; Black, A.; Bangma, C.H.; Schröder, F.H., 2010:
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit

Rodger, J.C.; Supramaniam, R.; Gibberd, A.J.; Smith, D.P.; Armstrong, B.K.; Dillon, A.; O'Connell, D.L., 2015:
Prostate cancer mortality outcomes and patterns of primary treatment for Aboriginal men in New South Wales, Australia

O'Lorcain, P.; Comber, H., 2007:
Prostate cancer mortality predictions for Ireland up to 2015

Roobol, M.J.; Kerkhof, M.; Schröder, F.H.; Cuzick, J.; Sasieni, P.; Hakama, M.; Stenman, U.Hakan.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; Denis, L.; Recker, F.; Berenguer, A.; Ruutu, M.; Kujala, P.; Bangma, C.H.; Aus, G.; Tammela, T.L.J.; Villers, A.; Rebillard, X.; Moss, S.M.; de Koning, H.J.; Hugosson, J.; Auvinen, A., 2010:
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

Walsh, L.; Dufey, F.; Tschense, A.; Schnelzer, M.; Sogl, M.; Kreuzer, M., 2012:
Prostate cancer mortality risk in relation to working underground in the Wismut cohort study of German uranium miners, 1970-2003

Niclis, C.; Pou, S.A.; Bengió, Rén.H.; Osella, A.R.; Díaz, Mía.Del.Pilar., 2011:
Prostate cancer mortality trends in Argentina 1986-2006: an age-period-cohort and joinpoint analysis

Delacroix, S.E.; Ward, J.F., 2011:
Prostate cancer multifocality: impact on cancer biology and treatment recommendations

Caras, R.J.; Sterbis, J.R., 2014:
Prostate cancer nomograms: a review of their use in cancer detection and treatment

Honn, K.V.; Aref, A.; Chen, Y.Q.; Cher, M.L.; Crissman, J.D.; Forman, J.D.; Gao, X.; Grignon, D.; Hussain, M.; Porter, A.T.; Pontes, J.E.; Powell, I.; Redman, B.; Sakr, W.; Severson, R.; Tang, D.G.; Wood, D.P., 1996:
Prostate cancer old problems and new approaches : Part I. epidemiology, incidence and genetic alterations

Anonymous, 2015:
Prostate cancer organoids make debut

Stoyanova, T.; Cooper, A.R.; Drake, J.M.; Liu, X.; Armstrong, A.J.; Pienta, K.J.; Zhang, H.; Kohn, D.B.; Huang, J.; Witte, O.N.; Goldstein, A.S., 2014:
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells

Sarafanov, A.G.; Todorov, T.I.; Centeno, Jé.A.; Macias, V.; Gao, W.; Liang, W-Min.; Beam, C.; Gray, M.A.; Kajdacsy-Balla, Aé.A., 2011:
Prostate cancer outcome and tissue levels of metal ions

Kabore, Féwindé.A.; Zango, Bé.; Sanou, A.; Yameogo, C.; Kirakoya, B., 2011:
Prostate cancer outcome in Burkina Faso

Tuppin, P.; Samson, Sène.; Fagot-Campagna, A.; Lukacs, B.; Alla, Fçois.; Paccaud, F.; Thalabard, J-Christophe.; Vicaut, E.; Vidaud, M.; Millat, B., 2014:
Prostate cancer outcomes in France: treatments, adverse effects and two-year mortality

Klotz, L., 2013:
Prostate cancer overdiagnosis and overtreatment

Drudge-Coates, L.; Turner, B., 2012:
Prostate cancer overview. Part 1: non-metastatic disease

Drudge-Coates, L.; Turner, B., 2013:
Prostate cancer overview. Part 2: metastatic prostate cancer

Bader, P.; Echtle, D.; Fonteyne, V.; Livadas, K.; D.M.erleer, G.; Paez Borda, A.; Papaioannou, E.G.; Vranken, J.H., 2013:
Prostate cancer pain management: EAU guidelines on pain management

D'Souza, N.; Loblaw, D.Andrew.; Mamedov, A.; Sugar, L.; Holden, L., 2012:
Prostate cancer pathology audits: is central pathology review still warranted?

Garos, S.; Kluck, A.; Aronoff, D., 2007:
Prostate cancer patients and their partners: differences in satisfaction indices and psychological variables

Morse, M.D.; McNeel, D.G., 2010:
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses

Dobson, R., 2008:
Prostate cancer patients with BRCA2 mutation face poor survival

Røder, M.Andreas.; Reinhardt, S.; Brasso, K.; Iversen, P., 2008:
Prostate cancer patients with lymph node metastasis. Outcome in a consecutive group of 59 patients

Geay, J-François., 2007:
Prostate cancer physiopathology, diagnosis and therapy

Major, J.M.; Klonoff-Cohen, H.S.; Pierce, J.P.; Slymen, D.J.; Saltzstein, S.L.; Macera, C.A.; Mercola, D.; Kattan, M.W., 2011:
Prostate cancer postoperative nomogram scores and obesity

Pourmand, G.Reza.; Allameh, F.; Mohammad, K.; Dehghani, S.; Pourmand, B.; Mehrsai, A.Rasoul.; Hosseini, S.Hamed., 2013:
Prostate cancer predicting factors: a preliminary report from Tehran

Ahn, J.; Kibel, A.S.; Park, J.Y.; Rebbeck, T.R.; Rennert, H.; Stanford, J.L.; Ostrander, E.A.; Chanock, S.; Wang, M-Hsi.; Mittal, R.D.; Isaacs, W.B.; Platz, E.A.; Hayes, R.B., 2011:
Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence

Garai, S.; Pandey, U., 2008:
Prostate cancer presenting as an endobronchial mass: a case report with literature review

Dubhashi, S.P.; Kumar, H.; Nath, S.R., 2012:
Prostate cancer presenting as cervical lymphadenopathy

Amonkar, S.J.; Zachariah, K.; Feggetter, J., 2007:
Prostate cancer presenting as neuropathic urinary retention

Keller, D.L., 2010:
Prostate cancer prevention (AUGUST 2009)

Barnard, R.James., 2008:
Prostate cancer prevention by nutritional means to alleviate metabolic syndrome

Oliver, T.; Lorinez, A.; Cuzick, J., 2009:
Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies

Cavadas, Vítor.; Osório, Lís.; Sabell, F.; Teves, F.; Branco, F.; Silva-Ramos, M., 2011:
Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort

Parekh, D.J., 2011:
Prostate cancer prevention with 5 alpha-reductase inhibitors

Gomes, R.; Rebello, Lúcia.Emilia.Figueiredo.de.Sousa.; de Araújo, Fábio.Carvalho.; do Nascimento, E.Ferreira., 2008:
Prostate cancer prevention: a review of the literature

Parnes, H.L.; House, M.G.; Tangrea, J.A., 2014:
Prostate cancer prevention: agent development strategies

Parnes, H.L., 2012:
Prostate cancer prevention: do the 5-ARIs make the grade?

Parnes, H.L.; House, M.G.; Tangrea, J.A., 2013:
Prostate cancer prevention: strategies for agent development

Moradi, M.; Mousavi, P.; Siemens, R.; Sauerbrei, E.; Boag, A.; Abolmaesumi, P., 2008:
Prostate cancer probability maps based on ultrasound RF time series and SVM classifiers

Nandana, S.; Chung, L.Wk., 2014:
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting

Anonymous, 2011:
Prostate cancer progression and obesity are linked. Men who are overweight or obese who have prostate cancer have an elevated risk of cancer progression compared to normal-weight men

Fernández, E.V.; Price, D.K.; Figg, W.D., 2014:
Prostate cancer progression attributed to autonomic nerve development: potential for therapeutic prevention of localized and metastatic disease

Reis, B.Sgarbi.; Jungbluth, A.A.; Frosina, D.; Holz, M.; Ritter, E.; Nakayama, E.; Ishida, T.; Obata, Y.; Carver, B.; Scher, H.; Scardino, P.T.; Slovin, S.; Subudhi, S.K.; Reuter, V.E.; Savage, C.; Allison, J.P.; Melamed, J.; Jäger, E.; Ritter, G.; Old, L.J.; Gnjatic, S., 2014:
Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein

Merkle, W., 2015:
Prostate cancer prophylaxis by dietary supplements: more than just an illusion?

Masters, J.R., 2011:
Prostate cancer proteomics

Talcott, J.A., 2007:
Prostate cancer quality of life: beyond initial treatment and the patient

Dong, Y.; Bey, E.A.; Li, L-Shan.; Kabbani, W.; Yan, J.; Xie, X-Jin.; Hsieh, J-Tsong.; Gao, J.; Boothman, D.A., 2010:
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation

Goldner, G.; Sljivic, S.; Oismueller, R.; Salinger, J.; Mittermüller, M.; Langsenlehner, T.; Harder, W.; Kametriser, G.; Eiter, H.; Nechvile, E., 2011:
Prostate cancer radiotherapy in Austria: overview on number of patients, intention to treat, and treatment techniques based on data from 2007

Wajsman, Z., 2014:
Prostate cancer recurrence - new prognostic factors are needed

Altieri, D.C.; Languino, L.R.; Lian, J.B.; Stein, J.L.; Leav, I.; van Wijnen, A.J.; Jiang, Z.; Stein, G.S., 2009:
Prostate cancer regulatory networks

Declerck, L.; Adenis, C.; Amela, E.; Caty, A.; Adenis, A.; Penel, N., 2012:
Prostate cancer related haemophagocytic syndrome: successful treatment with chemotherapy

Barve, A.; Jin, W.; Cheng, K., 2015 :
Prostate cancer relevant antigens and enzymes for targeted drug delivery

Ellinger, J.; von Rücker, A.; Wernert, N.; Büttner, R.; Bastian, P.J.; Müller, S.C., 2008:
Prostate cancer research. Biomarkers as promising options for optimized diagnosis and treatment

Goetz, T.; Burnett, A.L., 2015:
Prostate cancer risk after anti-androgen treatment for priapism

Whitman, E.J.; Pomerantz, M.; Chen, Y.; Chamberlin, M.M.; Furusato, B.; Gao, C.; Ali, A.; Ravindranath, L.; Dobi, A.; Sesterhenn, I.A.; Sestrehenn, I.A.; McLeod, D.G.; Srivastava, S.; Freedman, M.; Petrovics, G., 2010:
Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy

Cooper, P.R.; McGuire, B.B.; Helfand, B.T.; Loeb, S.; Hu, Q.; Catalona, W.J., 2011:
Prostate cancer risk alleles and their associations with other malignancies

Reinhardt, D.; Helfand, B.T.; Cooper, P.R.; Roehl, K.A.; Catalona, W.J.; Loeb, S., 2015:
Prostate cancer risk alleles are associated with prostate cancer volume and prostate size

Helfand, B.T.; Kan, D.; Modi, P.; Catalona, W.J., 2011:
Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination

Darlington, G.Ann.; Kreiger, N.; Lightfoot, N.; Purdham, J.; Sass-Kortsak, A., 2007:
Prostate cancer risk and diet, recreational physical activity and cigarette smoking

Band, P.R.; Abanto, Z.; Bert, J.; Lang, B.; Fang, R.; Gallagher, R.P.; Le, N.D., 2011:
Prostate cancer risk and exposure to pesticides in British Columbia farmers

Alexander, W., 2013:
Prostate cancer risk and omega-3 Fatty Acid intake from fish oil: a closer look at media messages versus research findings

Hoskote, S.S.; Nadkarni, G.N.; Fried, E.D., 2012:
Prostate cancer risk and vitamin E

Lundon, D.J.; Kelly, B.D.; Foley, R.; Loeb, S.; Fitzpatrick, J.M.; Watson, R.W.G.; Rogers, E.; Durkan, G.C.; Walsh, K., 2016:
Prostate cancer risk assessment tools in an unscreened population

Cooperberg, M.R., 2008:
Prostate cancer risk assessment: choosing the sharpest tool in the shed

Xu, J.; Kibel, A.S.; Hu, J.J.; Turner, A.R.; Pruett, K.; Zheng, S.Lilly.; Sun, J.; Isaacs, S.D.; Wiley, K.E.; Kim, S-Tae.; Hsu, F-Chi.; Wu, W.; Torti, F.M.; Walsh, P.C.; Chang, B-Li.; Isaacs, W.B., 2009:
Prostate cancer risk associated loci in African Americans

Thomas, J-Alfred.; Gerber, L.; Bañez, L.L.; Moreira, D.M.; Rittmaster, R.S.; Andriole, G.L.; Freedland, S.J., 2012:
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study

Onitilo, A.A.; Berg, R.L.; Engel, J.M.; Stankowski, R.V.; Glurich, I.; Williams, G.M.; Doi, S.A.R., 2014:
Prostate cancer risk in pre-diabetic men: a matched cohort study

Mao, Y-Qing.; Xu, X.; Lin, Y-Wei.; Chen, H.; Hu, Z-Hui.; Xu, X-Lai.; Zhu, Y.; Wu, J.; Zheng, X-Yi.; Qin, J.; Xie, L-Ping., 2014:
Prostate cancer risk in relation to a single nucleotide polymorphism in the insulin-like growth factor-binding protein-3 (IGFBP3) gene: a meta-analysis

Mikami, K.; Ozasa, K.; Nakao, M.; Miki, T.; Hayashi, K.; Watanabe, Y.; Mori, M.; Sakauchi, F.; Washio, M.; Kubo, T.; Suzuki, K.; Wakai, K.; Nakachi, K.; Tajima, K.; Ito, Y.; Inaba, Y.; Tamakoshi, A.; Tamakoshi, A.; Mori, M.; Sakauchi, F.; Motohashi, Y.; Tsuji, I.; Nakamura, Y.; Iso, H.; Mikami, H.; Kurosawa, M.; Hoshiyama, Y.; Tanabe, N.; Tamakoshi, K.; Wakai, K.; Tokudome, S.; Suzuki, K.; Hashimoto, S.; Kikuchi, S.; Wada, Y.; Kawamura, T.; Watanabe, Y.; Ozasa, K.; Miki, T.; Date, C.; Sakata, K., 2010:
Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan

Van Hemelrijck, M.; Garmo, H.; Holmberg, L.; Walldius, Göran.; Jungner, I.; Hammar, N.; Lambe, M., 2011:
Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose

Robertson, N.L.; Hu, Y.; Ahmed, H.U.; Freeman, A.; Barratt, D.; Emberton, M., 2014:
Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study

Luedeke, M.; Coinac, I.; Linnert, C.M.; Bogdanova, N.; Rinckleb, A.E.; Schrader, M.; Vogel, W.; Hoegel, J.; Meyer, A.; Dörk, T.; Maier, C., 2012:
Prostate cancer risk is not altered by TP53AIP1 germline mutations in a German case-control series

Du, M.; Yuan, T.; Schilter, K.F.; Dittmar, R.L.; Mackinnon, A.; Huang, X.; Tschannen, M.; Worthey, E.; Jacob, H.; Xia, S.; Gao, J.; Tillmans, L.; Lu, Y.; Liu, P.; Thibodeau, S.N.; Wang, L., 2015:
Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome

Albright, F.; Stephenson, R.A.; Agarwal, N.; Teerlink, C.C.; Lowrance, W.T.; Farnham, J.M.; Albright, L.A.Cannon., 2015:
Prostate cancer risk prediction based on complete prostate cancer family history

Lichtensztajn, D.Y.; Gomez, S.Lin.; Sieh, W.; Chung, B.I.; Cheng, I.; Brooks, J.D., 2014:
Prostate cancer risk profiles of Asian-American men: disentangling the effects of immigration status and race/ethnicity

Szulkin, R.; Holmberg, E.; Stattin, Pär.; Xu, J.; Zheng, S.; Palmgren, J.; Grönberg, H.; Wiklund, F., 2012:
Prostate cancer risk variants are not associated with disease progression

Kim, S-Tae.; Cheng, Y.; Hsu, F-Chi.; Jin, T.; Kader, A.Karim.; Zheng, S.Lilly.; Isaacs, W.B.; Xu, J.; Sun, J., 2010:
Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation

Andriole, G.L., 2009:
Prostate cancer risk: overview of the disease, predictive factors, and potential targets for risk reduction. Introduction

Sandblom, G.; Varenhorst, E., 2008:
Prostate cancer screening

Cook, E.D.; Nelson, A.C., 2011:
Prostate cancer screening

Sikaris, K., 2012:
Prostate cancer screening

Ragsdale, J.W.; Halstater, B.; Martinez-Bianchi, V., 2015:
Prostate cancer screening

Chaldakov, G.N., 2018:
Colchicine, a microtubule-disassembling drug, in the therapy of cardiovascular diseases

Ma, G.X.; Shive, S.E.; Gao, W.; Tan, Y.; Wang, M.Qi., 2012:
Prostate cancer screening among chinese american men: a structural model

Glenn, B.A.; Bastani, R.; Maxwell, A.E.; Mojica, C.M.; Herrmann, A.K.; Gallardo, N.V.; Swanson, K.A.; Chang, L.Cindy., 2013:
Prostate cancer screening among ethnically diverse first-degree relatives of prostate cancer cases

Bowden, F.J.; Roberts, J.; Collignon, P.J., 2008:
Prostate cancer screening and bacteraemia

Catalona, W.J.; Loeb, S., 2010:
Prostate cancer screening and determining the appropriate prostate-specific antigen cutoff values

Walsh, R.M.; Thompson, I.M., 2007:
Prostate cancer screening and disease management: how screening may have an unintended effect on survival and mortality-the camel's nose effect

Mottet, N.; Bourmaud, Aélie.; Droz, J-Pierre., 2010:
Prostate cancer screening and early diagnosis

Ragupathy, R.; Menkes, D.B., 2014:
Prostate cancer screening and ethical use of limited resources

Sammon, J.David.; Sukumar, S.; Trinh, Q-Dien., 2013:
Prostate cancer screening and incidence: a question of causality

Delgado-Rodríguez, M., 2010:
Prostate cancer screening and mortality in a European Community trial

Mian, B.M., 2010:
Prostate cancer screening and mortality: comparison of recent randomized controlled clinical trials

Hsieh, M.H.; Meng, M.V., 2015:
Prostate cancer screening and risk of litigation: caught between Scylla and Charybdis

Williams, R.M.; Zincke, N.L.; Turner, R.O.; Davis, J.L.; Davis, K.M.; Schwartz, M.D.; Johnson, L.; Kerner, J.F.; Taylor, K.L., 2008:
Prostate cancer screening and shared decision-making preferences among African-American members of the Prince Hall Masons

Loeb, S., 2012:
Prostate cancer screening and surgical management of localized disease: highlights from the 27th annual congress of the European association of urology, february 24-28, 2012, paris, france

Rogers, C.Stewart., 2009:
Prostate cancer screening and surveillance

Wilt, T.J.; Ahmed, H.U., 2013:
Prostate cancer screening and the management of clinically localized disease

Breyer, B.N.; Whitson, J.M.; Freise, C.E.; Meng, M.V., 2009:
Prostate cancer screening and treatment in the transplant population: current status and recommendations

Fitzsimons, N.J.; Freedland, S.J., 2006:
Prostate cancer screening and treatment recommendations

Nakamura, T.; Etsunaga, T.; Sasaki, Y.; Nitta, T.; Okugi, Y.; Okazaki, H.; Katou, N.; Yamamoto, T.; Suzuki, K., 2007:
Prostate cancer screening at Tatebayashi City in Gunma prefecture--results of screening with PSA alone between 2003 and 2005

Papatsoris, A.; Anagnostopoulos, F., 2008:
Prostate cancer screening behaviour

Sayburn, A., 2015:
Prostate cancer screening can save lives but it is too early for a national programme, study finds

Thompson, I.M.; Tangen, C.M., 2014:
Prostate cancer screening comes of age

Hoffman, R.M.; Couper, M.P.; Zikmund-Fisher, B.J.; Levin, C.A.; McNaughton-Collins, M.; Helitzer, D.L.; VanHoewyk, J.; Barry, M.J., 2009:
Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study)

Carmichael, L.K.; Goldsbury, D.E.; O'Connell, D.L., 2014:
Prostate cancer screening for men aged 75 to 84 years in New South Wales

van Leeuwen, P.J., 2011:
Prostate cancer screening has no effect on prostate cancer specific mortality over 20 years of follow-up of Swedish men

Parchment, Y.D., 2008:
Prostate cancer screening in African American and Caribbean males: detriment in delay

Reynolds, D., 2009:
Prostate cancer screening in African American men: barriers and methods for improvement

Castro, E.; Goh, C.L.; Eeles, R.A., 2015:
Prostate cancer screening in BRCA and Lynch syndrome mutation carriers

Stamatiou, K.; Lardas, M.; Kostakos, E.; Koutsonasios, V.; Lepidas, D., 2009:
Prostate cancer screening in Greece: current facts

Suzuki, K., 2012:
Prostate cancer screening in Japan: current status and perspective

Gray, B., 2014:
Prostate cancer screening in New Zealand

Belbase, N.Prasad.; Agrawal, C.Shekhar.; Pokharel, P.Kumar.; Agrawal, S.; Lamsal, M.; Shakya, V.Chandra., 2015:
Prostate cancer screening in a healthy population cohort in eastern Nepal: an explanatory trial study

Hoffman, K.E.; Nguyen, P.L.; Ng, A.K.; D'Amico, A.V., 2010:
Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy

Grubb, R.L.; Pinsky, P.F.; Greenlee, R.T.; Izmirlian, G.; Miller, A.B.; Hickey, T.P.; Riley, T.L.; Mabie, J.E.; Levin, D.L.; Chia, D.; Kramer, B.S.; Reding, D.J.; Church, T.R.; Yokochi, L.A.; Kvale, P.A.; Weissfeld, J.L.; Urban, D.A.; Buys, S.S.; Gelmann, E.P.; Ragard, L.R.; Crawford, E.David.; Prorok, P.C.; Gohagan, J.K.; Berg, C.D.; Andriole, G.L., 2008:
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

Aupérin, A.; Laplanche, Aès.; Hill, C., 2007:
Prostate cancer screening in the general population: the drawbacks are certain but the benefits are hypothetical

Sothilingam, S.; Sundram, M.; Malek, R.; Sahabuddin, R.M., 2011:
Prostate cancer screening perspective, Malaysia

Glicksman, A.S.; Meyer, A.; Cullinen, K., 2009:
Prostate cancer screening practice and knowledge in Rhode Island

Richards, T.B.; Rim, S.Hee.; Hall, I.J.; Richardson, L.C.; Ross, L.E., 2012:
Prostate cancer screening practices of African-American and non-African-American US primary care physicians: a cross-sectional survey

Barton, M.Kay., 2014:
Prostate cancer screening rates remain stable despite recommendations against testing men with limited life expectancy

Kobayashi, T.; Goto, R.; Ito, K.; Mitsumori, K., 2007:
Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective

Wallner, L.; Frencher, S.; Hsu, J-Wen.; Loo, R.; Huang, J.; Nichol, M.; Jacobsen, S., 2013:
Prostate cancer screening trends in a large, integrated health care system

Sadi, M.V., 2014 :
Prostate cancer screening with PSA: "Aequanimitas"

Herwig, R.; Djavan, B.; Kramer, G.; El-Taieb, M.A.; Kühhas, F.; Leers, M.; Marberger, M., 2007:
Prostate cancer screening with a new marker based on circulating blood macrophages?

Diamandis, E.P., 2010:
Prostate cancer screening with prostate-specific antigen testing: more answers or more confusion?

Gomella, L.G., 2010:
Prostate cancer screening "reloaded"

Razi, A., 2007:
Prostate cancer screening, yes or no? The current controversy

Chou, R.; LeFevre, M.L., 2011:
Prostate cancer screening--the evidence, the recommendations, and the clinical implications

Kim, J.; Davis, J.W., 2011:
Prostate cancer screening--time to abandon one-size-fits-all approach?

Allard, C.B.; Dason, S.; Lusis, J.; Kapoor, A., 2012:
Prostate cancer screening: Attitudes and practices of family physicians in Ontario

Izawa, J.I.; Klotz, L.; Siemens, D.Robert.; Kassouf, W.; So, A.; Jordan, J.; Chetner, M.; Iansavichene, A.E., 2011:
Prostate cancer screening: Canadian guidelines 2011

Braillon, A.; Dubois, Gérard., 2007:
Prostate cancer screening: Unacceptable in the under 50s

Gaster, B., 2014:
Prostate cancer screening: a complicated puzzle, explanation needed

Pogodin-Hannolainen, D.; Juusela, H.; Tammela, T.L.J.; Ruutu, M.; Aro, J.; Määttänen, L.; Auvinen, A., 2011:
Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007

Holcomb, S.Simmons., 2007:
Prostate cancer screening: an individual decision

Tawadros, T.; Doerfler, A.; Treuthardt, C.; Praz, V.; Levi, F.; Zouhair, A.; Berthold, D.; Bauer, J.; Iselin, C.; Jichlinski, P., 2010:
Prostate cancer screening: an update

Anonymous, 2014:
Prostate cancer screening: at 40 instead of at 50

Brawley, O.W., 2013:
Prostate cancer screening: biases and the need for consensus

Fillée, C.; Tombal, B.; Philippe, M., 2010:
Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access prostate-specific antigen assays

Fingerman, M.; Fingerman, S.W.; Lambert, D.T., 2018:
Colchicine, Cytochalasin B, And Pigment Movements In Ovarian And Integumentary Erythrophores Of The Prawn, Palaemonetes Vulgaris

Mantha, M-Michèle., 2013:
Prostate cancer screening: genetic testing

Krahn, M., 2015:
Prostate cancer screening: going beyond the clinical evidence

Loeb, S., 2014:
Prostate cancer screening: highlights from the 29th European association of urology congress stockholm, sweden, april 11-15, 2014

O'Shaughnessy, M.; Konety, B.; Warlick, C., 2010:
Prostate cancer screening: issues and controversies

LeFevre, M., 2009:
Prostate cancer screening: let patients decide

Nau, J-Yves., 2009:
Prostate cancer screening: new data

Laplanche, Aès.; Hill, C., 2009:
Prostate cancer screening: no proof of the benefit

Wilbur, J., 2009:
Prostate cancer screening: the continuing controversy

Holmberg, L., 2010:
Prostate cancer screening: the need for problem-solving that puts men's interests first

Iselin, C.; Jichlinski, P., 2011:
Prostate cancer screening: utility, goals and perspectives in 2010

L.R.chelle, J.; Amling, C.L., 2010:
Prostate cancer screening: what we have learned from the PLCO and ERSPC trials

Brawley, O.W., 2012:
Prostate cancer screening: what we know, don't know, and believe

Thanel, F.H.; Huntington, M.K., 2010:
Prostate cancer screening: what's a fellow to do?

LeFevre, M., 2008:
Prostate cancer screening: why it's not for every man

Safarinejad, M.Reza., 2014:
Prostate cancer screening: yes or no?

Brawley, O.W., 2009:
Prostate cancer screening; is this a teachable moment?

Liu, X.; Langer, D.L.; Haider, M.A.; Yang, Y.; Wernick, M.N.; Yetik, I.Samil., 2009:
Prostate cancer segmentation with simultaneous estimation of Markov random field parameters and class

MacInnis, R.J.; Antoniou, A.C.; Eeles, R.A.; Severi, G.; Guy, M.; McGuffog, L.; Hall, A.L.; O'Brien, L.T.; Wilkinson, R.A.; Dearnaley, D.P.; Ardern-Jones, A.T.; Horwich, A.; Khoo, V.S.; Parker, C.C.; Huddart, R.A.; McCredie, M.R.; Smith, C.; Southey, M.C.; Staples, M.P.; English, D.R.; Hopper, J.L.; Giles, G.G.; Easton, D.F., 2010:
Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies

Burgess, E.F.; Ham, A-Joan.L.; Tabb, D.L.; Billheimer, D.; Roth, B.J.; Chang, S.S.; Cookson, M.S.; Hinton, T.J.; Cheek, K.L.; Hill, S.; Pietenpol, J.A., 2008:
Prostate cancer serum biomarker discovery through proteomic analysis of alpha-2 macroglobulin protein complexes

Miller, D.C.; Litwin, M.S.; Bergman, J.; Stepanian, S.; Connor, S.E.; Kwan, L.; Aronson, W.J., 2009:
Prostate cancer severity among low income, uninsured men

Zeigler-Johnson, C.M.; Tierney, A.; Rebbeck, T.R.; Rundle, A., 2011:
Prostate cancer severity associations with neighborhood deprivation

Kiernan, D., 2013:
Prostate cancer specialist nurse

Wright, J.L.; Salinas, C.A.; Lin, D.W.; Kolb, S.; Koopmeiners, J.; Feng, Z.; Stanford, J.L., 2009:
Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort

Mohamed, S.S.; Salama, M.A., 2008:
Prostate cancer spectral multifeature analysis using TRUS images

Falzarano, S.Moscovita.; Magi-Galluzzi, C., 2011:
Prostate cancer staging and grading at radical prostatectomy over time

Bischoff, M., 2014:
Prostate cancer staging: ¹ ¹ C-Acetat-PET/CT as a sensitive marker for nodal metastases

Yu, C.; Yao, Z.; Jiang, Y.; Keller, E.T., 2012:
Prostate cancer stem cell biology

Botchkina, G.I.; Zuniga, E.S.; Rowehl, R.H.; Park, R.; Bhalla, R.; Bialkowska, A.B.; Johnson, F.; Golub, L.M.; Zhang, Y.; Ojima, I.; Shroyer, K.R., 2014:
Prostate cancer stem cell-targeted efficacy of a new-generation taxoid, SBT-1214 and novel polyenolic zinc-binding curcuminoid, CMC2.24

Lang, S.H.; Frame, F.M.; Collins, A.T., 2009:
Prostate cancer stem cells

Romańska-Knight, H.; Abel, P., 2011:
Prostate cancer stem cells

Tu, S-Ming.; Lin, S-Hwa., 2012:
Prostate cancer stem cells

Li, H.; Tang, D.G., 2011:
Prostate cancer stem cells and their potential roles in metastasis

Jachetti, E.; Mazzoleni, S.; Grioni, M.; Ricupito, A.; Brambillasca, C.; Generoso, L.; Calcinotto, A.; Freschi, M.; Mondino, A.; Galli, R.; Bellone, M., 2013:
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses

Hynes, P.G.; Kelly, K., 2012:
Prostate cancer stem cells: The case for model systems

Maitland, N.J.; Collins, A.T., 2008:
Prostate cancer stem cells: a new target for therapy

Maitland, N.J.; Frame, F.M.; Polson, E.S.; Lewis, J.L.; Collins, A.T., 2011:
Prostate cancer stem cells: do they have a basal or luminal phenotype?

Yan, J.; Tang, D., 2014:
Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response

Halpin, M.; Phillips, M.; Oliffe, J.L., 2008:
Prostate cancer stories in the Canadian print media: representations of illness, disease and masculinities

Mizokami, A.; Koh, E.; Izumi, K.; Narimoto, K.; Takeda, M.; Honma, S.; Dai, J.; Keller, E.T.; Namiki, M., 2010:
Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone

Oliffe, J.L.; Bottorff, J.L.; McKenzie, M.M.; Hislop, T.Gregory.; Gerbrandt, J.S.; Oglov, V., 2012:
Prostate cancer support groups, health literacy and consumerism: are community-based volunteers re-defining older men's health?

Oliffe, J.L.; Chambers, S.; Garrett, B.; Bottorff, J.L.; McKenzie, M.; Han, C.S.; Ogrodniczuk, J.S., 2015:
Prostate cancer support groups: Canada-based specialists' perspectives

Costello, A.J., 2014:
Prostate cancer surgery vs radiation: has the fat lady sung?

Cormier, L.; Bastide, C.; Beuzeboc, P.; Fromont, G.; Hennequin, C.; Mongiat-Artus, P.; Peyromaure, M.; Ploussard, G.; Renard-Penna, R.; Richaud, P.; Rozet, F.; Soulié, M.; Salomon, L., 2015:
Prostate cancer surgical margin: review by the CCAFU (Oncology Committee of the French Association of Urology)

Mungrue, K.; Moonan, S.; Mohammed, M.; Hyatali, S., 2011:
Prostate cancer survival in Trinidad: Is PSA a prognostic factor?

Vijaykumar, S.; Wray, R.J.; Jupka, K.; Clarke, R.; Shahid, M., 2014:
Prostate cancer survivors as community health educators: implications for informed decision making and cancer communication

Thong, M.S.Y.; Mols, F.; Kil, P.J.M.; Korfage, I.J.; van de Poll-Franse, L.V., 2010:
Prostate cancer survivors who would be eligible for active surveillance but were either treated with radiotherapy or managed expectantly: comparisons on long-term quality of life and symptom burden

Orom, H.; Underwood, W.; Homish, D.Lynn.; Kiviniemi, M.T.; Homish, G.G.; Nelson, C.J.; Schiffman, Z., 2014:
Prostate cancer survivors' beliefs about screening and treatment decision-making experiences in an era of controversy

Anonymous, 2014:
Prostate cancer survivorship guidelines

Goonewardene, S.S.; Nanton, V.; Young, A.; Persad, R.; Makar, A., 2016:
Prostate cancer survivorship: a new path for uro-oncology

Chung, E.; Gillman, M., 2014:
Prostate cancer survivorship: a review of erectile dysfunction and penile rehabilitation after prostate cancer therapy

Goonewardene, S.S.; Persad, R.; Nanton, V.; Young, A.; Makar, A., 2016:
Prostate cancer survivorship: lifestyle changes, much needed!

Saylor, P.J.; Keating, N.L.; Smith, M.R., 2010:
Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy

Bonilla, C.; Hooker, S.; Mason, T.; Bock, C.H.; Kittles, R.A., 2011:
Prostate cancer susceptibility Loci identified on chromosome 12 in African Americans

Ostrander, E.A.; Johannesson, B., 2008:
Prostate cancer susceptibility loci: finding the genes

Amankwah, E.K.; Kelemen, L.E.; Wang, Q.; Song, H.; Chenevix-Trench, G.; Beesley, J.; Webb, P.M.; Pearce, C.L.; Wu, A.H.; Pike, M.C.; Stram, D.O.; Chang-Claude, J.; Wang-Gohrke, S.; Ness, R.B.; Goode, E.L.; Cunningham, J.M.; Fridley, B.L.; Vierkant, R.A.; Tworoger, S.S.; Whittemore, A.S.; McGuire, V.; Sieh, W.; Gayther, S.A.; Gentry-Maharaj, A.; Menon, U.; Ramus, S.J.; Rossing, M.Anne.; Doherty, J.A.; Goodman, M.T.; Carney, M.E.; Lurie, G.; Wilkens, L.R.; Kjær, S.Krüger.; Høgdall, E.; Cramer,, 2011:
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer

Cheng, I.; Plummer, S.J.; Neslund-Dudas, C.; Klein, E.A.; Casey, G.; Rybicki, B.A.; Witte, J.S., 2011:
Prostate cancer susceptibility variants confer increased risk of disease progression

Taylor, R.M.; Severns, V.; Brown, D.C.; Bisoffi, M.; Sillerud, L.O., 2012:
Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts

Ross, T., 2007:
Prostate cancer telephone helpline: nursing from a different perspective

Crowe, J.; Wootten, A.C.; Howard, N., 2015:
Prostate cancer testing: a snapshot of the attitudes and practice of Australian general practitioners

Izard, J.P.; True, L.D.; May, P.; Ellis, W.J.; Lange, P.H.; Dalkin, B.; Lin, D.W.; Schmidt, R.A.; Wright, J.L., 2014:
Prostate cancer that is within 0.1 mm of the surgical margin of a radical prostatectomy predicts greater likelihood of recurrence

Pawlicki, T.; Cotrutz, C.; King, C., 2007:
Prostate cancer therapy with stereotactic body radiation therapy

Saad, F., 2012:
Prostate cancer therapy: finding the right balance

Sweeney, C., 2013:
Prostate cancer therapy: going forwards by going backwards

Ellinger, J.; Bastian, P.J.; Biermann, K.; Schmidt, M.E.; Textor, J.; Bollmann, D.; Zhou, H.; Müller, S.C., 2007:
Prostate cancer tissue is masked by bicalutamide: a case report

Tokuda, Y.; Carlino, L.J.; Gopalan, A.; Tickoo, S.K.; Kaag, M.G.; Guillonneau, B.; Eastham, J.A.; Scher, H.I.; Scardino, P.T.; Reuter, V.E.; Fine, S.W., 2010:
Prostate cancer topography and patterns of lymph node metastasis

Rouvière, O.; Girouin, N.; Glas, L.; Ben Cheikh, A.; Gelet, A.; Mège-Lechevallier, F.; Rabilloud, M.; Chapelon, J-Yves.; Lyonnet, D., 2010:
Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI

Adler, R.A., 2014:
Prostate cancer treated with androgen deprivation therapy has consequences for bone

Prezioso, D.; Galasso, R.; D.M.rtino, M.; Iapicca, G., 2007:
Prostate cancer treatment and quality of life

Bradley, C.J.; Dahman, B.; Anscher, M., 2014:
Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions

Repetto, L.M.; Abbatecola, A.Marie.; Paolisso, G., 2013:
Prostate cancer treatment choices

Khochikar, M.V., 2007:
Prostate cancer treatment does not increase the risk of cardiovascular events

Parsons, J.Kellogg.; Kwan, L.; Connor, S.E.; Miller, D.C.; Litwin, M.S., 2010:
Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers

Gatta, G.; Zigon, G.; Buemi, A.; Coebergh, J.Willem.; Colonna, M.; Contiero, P.; Denis, L.; Grosclaude, P.; Guizard, A.Valèrie.; Sanchez-Perez, M.Jose.; Plesko, I.; Ondrusova, M.; Rachtan, J.; Valdagni, R.; Velten, M.; Vercelli, M.; Berrino, F., 2010:
Prostate cancer treatment in Europe at the end of 1990s

Shimer, S.Elana., 2014:
Prostate cancer treatment modalities and survival outcomes: a comparative analysis of Falmouth Hospital versus Massachusetts and nationwide hospitals

Xiao, H.; Warrick, C.; Huang, Y., 2010:
Prostate cancer treatment patterns among racial/ethnic groups in Florida

Tsivian, M.; Abern, M.R.; Polascik, T.J., 2012:
Prostate cancer treatment unblinded

Kirby, R.; Challacombe, B.; Dasgupta, P.; Fitzpatrick, J.M., 2013:
Prostate cancer treatment: the times they are a' changin'

Kaitouni, M.Idrissi.; Roumeguère, T., 2010:
Prostate cancer treatments in Belgium

Singh, P.B.; Anele, C.; Dalton, E.; Barbouti, O.; Stevens, D.; Gurung, P.; Arya, M.; Jameson, C.; Freeman, A.; Emberton, M.; Ahmed, H.U., 2015:
Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy

Sciarra, A.; Salciccia, S.; Gentilucci, A.; Innocenzi, M.; Alfarone, A.; Cattarino, S.; Ravaziol, M.; Panebianco, V., 2015:
Prostate cancer unit for an optimal management of prostate cancer unit

Valdagni, R., 2012:
Prostate cancer units: has the time come to discuss this thorny issue and promote their establishment in Europe?

Denis, L., 2012:
Prostate cancer units: the patients' perspective

Lin, A.M.; Small, E.J., 2007:
Prostate cancer update: 2006

Lin, A.M.; Small, E.J., 2008:
Prostate cancer update: 2007

Anonymous, 2007:
Prostate cancer update: advances in disease management over the past 20 years. Proceedings of a meeting. September 2006. Budapest, Hungary

Michael, A.; Relph, K.; Annels, N.; Pandha, H., 2013:
Prostate cancer vaccines

Lubaroff, D.M., 2012:
Prostate cancer vaccines in clinical trials

Uhlman, M.A.; Bing, M.T.; Lubaroff, D.M., 2015 :
Prostate cancer vaccines in combination with additional treatment modalities

Geary, S.M.; Salem, A.K., 2013:
Prostate cancer vaccines: Update on clinical development

Arlen, P.M., 2013:
Prostate cancer vaccines: an old yet novel target, the androgen receptor

Slovin, S.F., 2008:
Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome

Arlen, P.M.; Wood, L.V., 2012:
Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era

Siegel, C., 2016:
Prostate cancer vs. post-biopsy hemorrhage: diagnosis with T2- and diffusion-weighted imaging

Drewa, T.; Jasinski, M.; Marszalek, A.; Chlosta, P., 2011:
Prostate cancer which affects an elderly man is a feature of senescence (cellular) - a biology phenomenon

Park, K.; Chen, Z.; MacDonald, T.Y.; Siddiqui, J.; Ye, H.; Erbersdobler, A.; Shevchuk, M.M.; Robinson, B.D.; Sanda, M.G.; Chinnaiyan, A.M.; Beltran, H.; Rubin, M.A.; Mosquera, J.Miguel., 2014:
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification

Wu, A.; Kunju, L.P., 2013:
Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics

Kerkeni, W.; Bouzouita, A.; Selmi, M.Slim.; Kourda, N.; Cherif, M.; Derouich, A.; Zermani, R.; Ben Slama, M.Riadh.; Chebil, M., 2014:
Prostate cancer with bilateral testicular metastasis

Varinot, J.; Drouin, S.; Rouprêt, M.; Montironi, R.; Lopez-Beltran, A.; Compérat, E., 2013:
Prostate cancer with clear cell features and an unusual nested-like pattern of growth: a case report

Kim, H.; Shoji, S.; Tomonaga, T.; Shima, M.; Terachi, T.; Uchida, T., 2014:
Prostate cancer with cyst formation detected by whole body positron emission tomography/computed tomography: A case report

Minato, N.; Takada, T.; Koga, M.; Sugao, H., 2012:
Prostate cancer with disseminated carcinomatosis of bone marrow initially presenting with disseminated intravascular coagulation syndrome: a case report

Chen, J.; Quan, C-Yi.; Chang, J-Wu.; Yang, Y-Ming.; Li, B.; Chang, W-Liang.; Wang, J.; Niu, Y-Jie., 2012:
Prostate cancer with five different histological features: a case report and review of the literature

Sharma, P.; Karunanithi, S.; Singh Dhull, V.; Jain, S.; Bal, C.; Kumar, R., 2013:
Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy

Khan, F.; Mahmalji, W.; Sriprasad, S.; Madaan, S., 2014:
Prostate cancer with metastases to the kidney: a rare manifestation of a common disease

Zagouri, F.; Papaefthimiou, M.; Chalazonitis, A.N.; Antoniou, N.; Dimopoulos, M-Athanasios.; Bamias, A., 2010:
Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease

Glück, G.; Mihai, M.; Stoica, R.; Andrei, R.; Sinescu, I., 2012:
Prostate cancer with neuroendocrine differentiation--case report

Kim, S-Ouck.; Choi, Y.Duk.; Jung, S.Il.; Oh, K.Jin.; Im, C.Min.; Kang, T.Won.; Kwon, D.; Park, K.; Ryu, S.Bang., 2011:
Prostate cancer with solitary metastases to the bilateral testis

Trpkov, K.; Zhang, J.; Chan, M.; Eigl, B.J.C.; Yilmaz, A., 2008:
Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression

Cai, L.; Huang, W.; Chou, K-Chen., 2012:
Prostate cancer with variants in CYP17 and UGT2B17 genes: a meta-analysis

Long, T.J.; Sprenger, C.C.; Plymate, S.R.; Ratner, B.D., 2015:
Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape

Volland, A., 2007:
Prostate cancer's prognosis

Mohler, J.L.; Armstrong, A.J.; Bahnson, R.R.; Boston, B.; Busby, J.Erik.; D'Amico, A.Victor.; Eastham, J.A.; Enke, C.A.; Farrington, T.; Higano, C.S.; Horwitz, E.Mark.; Kantoff, P.W.; Kawachi, M.H.; Kuettel, M.; Lee, R.J.; MacVicar, G.R.; Malcolm, A.W.; Miller, D.; Plimack, E.R.; Pow-Sang, J.M.; Roach, M.; Rohren, E.; Rosenfeld, S.; Srinivas, S.; Strope, S.A.; Tward, J.; Twardowski, P.; Walsh, P.C.; Ho, M.; Shead, D.A., 2013:
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

Collier, A.; Ghosh, S.; McGlynn, B.; Hollins, G., 2012:
Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review

Coloby, P.; Boccon-Gibod, L.; Coulange, C.; Culine, S.; Davin, J-L.; Richaud, P.; Zerbib, M.; Soulié, M., 2013:
Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management

Reinoso Hermida, S.; Díaz Grávalos, G.J.; Robles Castiñeiras, A.; Villar Latorre, C.; López González, A.; Ojea Calvo, A., 2011:
Prostate cancer, antiandrogen treatment and cardiovascular risk

Chao, H.H.; Mayer, T.; Concato, J.; Rose, M.G.; Uchio, E.; Kelly, W.Kevin., 2010:
Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy

Tombal, B., 2010:
Prostate cancer, depression, and risk of suicide: should we pay more attention?

Wassersug, R.J., 2015:
Prostate cancer, gonadal hormones, and my brain

Mróz, L.W.; Chapman, G.E.; Oliffe, J.L.; Bottorff, J.L., 2011:
Prostate cancer, masculinity and food. Rationales for perceived diet change

Pekarik, V.; Gumulec, J.; Masarik, M.; Kizek, R.; Adam, V., 2014:
Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs

Häggström, C.; Stocks, T.; Nagel, G.; Manjer, J.; Bjørge, T.; Hallmans, Göran.; Engeland, A.; Ulmer, H.; Lindkvist, Börn.; Selmer, R.; Concin, H.; Tretli, S.; Jonsson, Håkan.; Stattin, Pär., 2015:
Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations

Schwartz, G.G., 2008:
Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases

Bouregba, A.; Lebret, T., 2008:
Prostate cancer, the urologist, the patient, and treatment

Rouprêt, M., 2008:
Prostate cancer, urinary incontinence, cancer of the testis

Mohler, J.L.; Kantoff, P.W.; Armstrong, A.J.; Bahnson, R.R.; Cohen, M.; D'Amico, A.Victor.; Eastham, J.A.; Enke, C.A.; Farrington, T.A.; Higano, C.S.; Horwitz, E.Mark.; Kawachi, M.H.; Kuettel, M.; Lee, R.J.; Macvicar, G.R.; Malcolm, A.W.; Miller, D.; Plimack, E.R.; Pow-Sang, J.M.; Richey, S.; Roach, M.; Rohren, E.; Rosenfeld, S.; Small, E.J.; Srinivas, S.; Stein, C.; Strope, S.A.; Tward, J.; Walsh, P.C.; Shead, D.A.; Ho, M., 2014:
Prostate cancer, version 1.2014

Mohler, J.L.; Kantoff, P.W.; Armstrong, A.J.; Bahnson, R.R.; Cohen, M.; D'Amico, A.Victor.; Eastham, J.A.; Enke, C.A.; Farrington, T.A.; Higano, C.S.; Horwitz, E.Mark.; Kane, C.J.; Kawachi, M.H.; Kuettel, M.; Kuzel, T.M.; Lee, R.J.; Malcolm, A.W.; Miller, D.; Plimack, E.R.; Pow-Sang, J.M.; Raben, D.; Richey, S.; Roach, M.; Rohren, E.; Rosenfeld, S.; Schaeffer, E.; Small, E.J.; Sonpavde, G.; Srinivas, S.; Stein, C.; Strope, S.A.; Tward, J.; Shead, D.A.; Ho, M., 2015:
Prostate cancer, version 2.2014

Lamb, D.S.; Bupha-Intr, O.; Bethwaite, P.; Murray, J.; Nacey, J.; Russell, G.; Delahunt, B., 2009:
Prostate cancer--are ethnic minorities disadvantaged?

Schröder, F.H.; van Weerden, W.M., 2010:
Prostate cancer--chemoprevention

Brasso, K., 2007:
Prostate cancer--incidence and risk factors

Dall'Era, M.; Carroll, P.R., 2007:
Prostate cancer--more information and more questions

Nakai, Y.; Tsujimura, A.; Nonomura, N., 2012:
Prostate cancer--the role of adrenal steroids

Rosser, C.J., 2009:
Prostate cancer--to screen, or not to screen, is that the question?

Thompson, I.M.; Tangen, C.M., 2012:
Prostate cancer--uncertainty and a way forward

Adkison, J.B.; Ritter, M.A., 2008:
Prostate cancer--which treatment to choose?

Qian, D.Z.; Huang, C-Ying.; O'Brien, C.A.; Coleman, I.M.; Garzotto, M.; True, L.D.; Higano, C.S.; Vessella, R.; Lange, P.H.; Nelson, P.S.; Beer, T.M., 2009:
Prostate cancer-associated gene expression alterations determined from needle biopsies

Geng, C.; He, B.; Xu, L.; Barbieri, C.E.; Eedunuri, V.Kumar.; Chew, S.Anne.; Zimmermann, M.; Bond, R.; Shou, J.; Li, C.; Blattner, M.; Lonard, D.M.; Demichelis, F.; Coarfa, C.; Rubin, M.A.; Zhou, P.; O'Malley, B.W.; Mitsiades, N., 2013:
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover

Chen, P-Chun.; Cheng, H-Chen.; Wang, J.; Wang, S-Wei.; Tai, H-Ching.; Lin, C-Wen.; Tang, C-Hsin., 2015:
Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment

Matsuoka, Y.; Arai, G.; Okada, Y.; Aida, J., 2009:
Prostate cancer-producing granulocyte colony-stimulating factor

Ding, M.; Cao, X.; Xu, H-neng.; Fan, J-kai.; Huang, H-ling.; Yang, D-qin.; Li, Y-hua.; Wang, J.; Li, R.; Liu, X-yuan., 2012:
Prostate cancer-specific and potent antitumor effect of a DD3-controlled oncolytic virus harboring the PTEN gene

van den Bergh, R.C.N.; Korfage, I.J.; Borsboom, G.J.J.M.; Steyerberg, E.W.; Essink-Bot, M-Louise., 2010:
Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer

Sawant, R.M.; Cohen, M.B.; Torchilin, V.P.; Rokhlin, O.W., 2008:
Prostate cancer-specific monoclonal antibody 5D4 significantly enhances the cytotoxicity of doxorubicin-loaded liposomes against target cells in vitro

Hoffman, K.E.; Chen, M-Hui.; Moran, B.J.; Braccioforte, M.H.; Dosoretz, D.; Salenius, S.; Katin, M.J.; Ross, R.; D'Amico, A.V., 2010:
Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer

Degroot, J.M.; Brundage, M.D.; Lam, M.; Rohland, S.L.; Heaton, J.; Mackillop, W.J.; Siemens, D.Robert.; Groome, P.A., 2013:
Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy

Froehner, M., 2011:
Prostate cancer-specific survival in elderly patients

Wadajkar, A.S.; Menon, J.U.; Tsai, Y-Shyan.; Gore, C.; Dobin, T.; Gandee, L.; Kangasniemi, K.; Takahashi, M.; Manandhar, B.; Ahn, J-Mo.; Hsieh, J-Tsong.; Nguyen, K.T., 2013:
Prostate cancer-specific thermo-responsive polymer-coated iron oxide nanoparticles

Lee, C-Moon.; Jeong, H-Jeong.; Cheong, S-Jin.; Kim, E-Mi.; Kim, D.Wook.; Lim, S.Tae.; Sohn, M-Hee., 2010:
Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin

Suzuki, K., 2012:
Prostate cancer-the role of docetaxel on castration-resistant prostate cancer: evaluation of efficacy and subsequent treatment

Mohler, J.; Babaian, R.J.; Bahnson, R.R.; Boston, B.; D'Amico, A.; Eastham, J.A.; Hauke, R.J.; Huben, R.P.; Kantoff, P.; Kawachi, M.; Kuettel, M.; Lange, P.H.; Logothetis, C.; MacVicar, G.; Pollack, A.; Pow-Sang, J.M.; Roach, M.; Sandler, H.; Shrieve, D.; Srinivas, S.; Twardowski, P.; Urban, D.A.; Walsh, P.C., 2007:
Prostate cancer. Clinical practice guidelines in oncology

Wirth, M.; Zastrow, S., 2012:
Prostate cancer. Current and practice-relevant news from urology in 2011

Bessissow, A.; Agzarian, J.; Shargall, Y.; Srinathan, S.; Neary, J.; Tandon, V.; Finley, C.; Healey, J.S.; Conen, D.; Rodseth, R.; Pettit, S.; Dechert, W.; Regalado, O.; Ramasundarahettige, C.; Alshalash, S.; Devereaux, P.J., 2017:
Colchicine for Prevention of Perioperative Atrial Fibrillation in patients undergoing lung resection surgery: a pilot randomized controlled study

Montagut, C.; Albanell, J.; Bellmunt, J., 2008:
Prostate cancer. Multidisciplinary approach: a key to success

Anonymous, 2009:
Prostate cancer. NCCN clinical practice guidelines in oncology

Theurillat, J-Philippe.P.; Udeshi, N.D.; Errington, W.J.; Svinkina, T.; Baca, S.C.; Pop, M.; Wild, P.J.; Blattner, M.; Groner, A.C.; Rubin, M.A.; Moch, H.; Privé, G.G.; Carr, S.A.; Garraway, L.A., 2014:
Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer

Chabanova, E.; Balslev, I.; Logager, V.; Hansen, A.; Jakobsen, H.; Kromann-Andersen, B.; Norgaard, N.; Horn, T.; Thomsen, H.S., 2012:
Prostate cancer: 1.5 T endo-coil dynamic contrast-enhanced MRI and MR spectroscopy--correlation with prostate biopsy and prostatectomy histopathological data

Panebianco, V.; Sciarra, A.; Lisi, D.; Galati, F.; Buonocore, V.; Catalano, C.; Gentile, V.; Laghi, A.; Passariello, R., 2012:
Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP)

Skinner, M., 2010:
Prostate cancer: A new tARget

Rosenkrantz, A.B.; Neil, J.; Kong, X.; Melamed, J.; Babb, J.S.; Taneja, S.S.; Taouli, B., 2010:
Prostate cancer: Comparison of 3D T2-weighted with conventional 2D T2-weighted imaging for image quality and tumor detection

Horwich, A.; Parker, C.; de Reijke, T.; Kataja, V., 2014:
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Horwich, A.; Hugosson, J.; de Reijke, T.; Wiegel, T.; Fizazi, K.; Kataja, V.; Parker, C.; Bellmunt, J.; Berthold, D.; Bill-Axelson, A.; Carlsson, S.; Daugaard, G.; D.M.erleer, G.; de Reijke, T.; Dearnaley, D.; Fizazi, K.; Fonteyne, Vérie.; Gillessen, S.; Heinrich, D.; Horwich, A.; Hugosson, J.; Kataja, V.; Kwiatkowski, M.; Nilsson, S.; Padhani, A.; Papandreou, C.; Parker, C.; Roobol, M.; Sella, A.; Valdagni, R.; Van der Kwast, T.; Verhagen, P.; Wiegel, T., 2013:
Prostate cancer: ESMO Consensus Conference Guidelines 2012

Horwich, A.; Parker, C.; Kataja, V., 2008:
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

Horwich, A.; Parker, C.; Kataja, V., 2010:
Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

Peko, J-F.; Odzebe, A.W.S.; Nsonde-Malanda, J.; Bambara, A.T.; Ngolet, A., 2012:
Prostate cancer: Gleason scores correlation between biopsies and surgical gross specimen

McArdle, S.Eb.; Pockley, A.Graham.; Gibson, G.R.; Rees, R.C., 2014:
Prostate cancer: Important steps and considerations in the design of therapeutic vaccines

Liebermann, D.A.; Hoffman, B., 2012:
Prostate cancer: JunD, Gadd45a and Gadd45g as therapeutic targets

Vogl, T.J.; Mayer, H.P.; Zangos, S.; Selby, J.Bayne.; Ackermann, H.; Mayer, F.B., 2007:
Prostate cancer: MR imaging-guided galvanotherapy--technical development and first clinical results

Jadvar, H., 2011:
Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline

Favorito, L.A., 2014:
Prostate cancer: Prognosis and recurrence

Tadayyon, F.; Mellat, M.; Alizadeh, F.; Hadi, M.; Khorrami, M.; Yazdani, M.; Joozdani, R.Hashemi., 2013:
Prostate cancer: Relationship between vascular diameter, shape and density and Gleason score in needle biopsy specimens

Cathomas, R., 2016:
Prostate cancer: a changing disease

Doyle-Lindrud, S., 2007:
Prostate cancer: a chronic illness

Gomella, L.G., 2014:
Prostate cancer: a high value target for cost containment

Balasubramaniam, G.; Talole, S.; Mahantshetty, U.; Saoba, S.; Shrivastava, S., 2013:
Prostate cancer: a hospital-based survival study from Mumbai, India

Bonaccorsi, L.; Nosi, D.; Quercioli, F.; Formigli, L.; Zecchi, S.; Maggi, M.; Forti, G.; Baldi, E., 2008:
Prostate cancer: a model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model

Gat, Y.; Joshua, S.; Gornish, M.G., 2009:
Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation

Lund, L.; Svolgaard, N.; Poulsen, M.Hvid., 2014:
Prostate cancer: a review of active surveillance

Winterhalder, R.C., 2009:
Prostate cancer: a review of therapeutic strategies

Fitzpatrick, J.M.; Schulman, C.; Zlotta, A.R.; Schröder, F.H., 2009:
Prostate cancer: a serious disease suitable for prevention

Bloch, B.Nicolas.; Furman-Haran, E.; Helbich, T.H.; Lenkinski, R.E.; Degani, H.; Kratzik, C.; Susani, M.; Haitel, A.; Jaromi, S.; Ngo, L.; Rofsky, N.M., 2007:
Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results

Yu, J-Sik.; Chung, J-Joon.; Hong, S.Won.; Chung, B.Ha.; Kim, J.Hee.; Kim, K.Whang., 2008:
Prostate cancer: added value of subtraction dynamic imaging in 3T magnetic resonance imaging with a phased-array body coil

Tefekli, A.; Tunc, M.; Tugcu, V.; Esen, Tık., 2014:
Prostate cancer: all aspects

Caso, J.R.; Mouraviev, V.; Tsivian, M.; Polascik, T.J.; Moul, J.W., 2010:
Prostate cancer: an evolving paradigm

Su, L.Joseph.; Fontham, E.T.H., 2015:
Prostate cancer: an occupational hazard?

Hohenfellner, M., 2011:
Prostate cancer: an update

Lim, H.Kyung.; Kim, J.Kon.; Kim, K.Ah.; Cho, K-Sik., 2008:
Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study

Palma dos Reis, Jé., 2015:
Prostate cancer: are we able to diagnose those in need? And are those that are diagnosed and treated those that are effectively in need?

Nanton, V.; Dale, J., 2009:
Prostate cancer: balancing the need to inform with the patient's wish to know

Loda, M.; Kaelin, W.G., 2010:
Prostate cancer: beta control your hormones

Heijmink, S.W.T.P.J.; Fütterer, J.J.; Hambrock, T.; Takahashi, S.; Scheenen, T.W.J.; Huisman, H.J.; Hulsbergen-Van de Kaa, C.A.; Knipscheer, B.C.; Kiemeney, L.A.L.M.; Witjes, J.Alfred.; Barentsz, J.O., 2007:
Prostate cancer: body-array versus endorectal coil MR imaging at 3 T--comparison of image quality, localization, and staging performance

Turkbey, B.; Mani, H.; Aras, O.; Ho, J.; Hoang, A.; Rastinehad, A.R.; Agarwal, H.; Shah, V.; Bernardo, M.; Pang, Y.; Daar, D.; McKinney, Y.L.; Linehan, W.Marston.; Kaushal, A.; Merino, M.J.; Wood, B.J.; Pinto, P.A.; Choyke, P.L., 2013:
Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

Lefi, M.; Hellara, W.; Touffahi, M.; Fredj, N.; Adnene, M.; Saidi, R.; Saad, H., 2008:
Prostate cancer: comparative study of stage T1a and stage T1b

Rosenkrantz, A.B.; Sabach, A.; Babb, J.S.; Matza, B.W.; Taneja, S.S.; Deng, F-Ming., 2013:
Prostate cancer: comparison of dynamic contrast-enhanced MRI techniques for localization of peripheral zone tumor

Rosenkrantz, A.B.; Kong, X.; Niver, B.E.; Berkman, D.S.; Melamed, J.; Babb, J.S.; Taneja, S.S., 2011:
Prostate cancer: comparison of tumor visibility on trace diffusion-weighted images and the apparent diffusion coefficient map

Hambrock, T.; Vos, P.C.; Hulsbergen-van de Kaa, C.A.; Barentsz, J.O.; Huisman, H.J., 2013:
Prostate cancer: computer-aided diagnosis with multiparametric 3-T MR imaging--effect on observer performance

Boyle, P.; Brawley, O.W., 2009:
Prostate cancer: current evidence weighs against population screening

Khoo, V.; Loblaw, D.A., 2014:
Prostate cancer: current status, new developments and applications in radiotherapy

Chen, F-Zhi.; Zhao, X-Kun., 2013:
Prostate cancer: current treatment and prevention strategies

Heesakkers, R.A.M.; Jager, G.J.; Hövels, A.M.; de Hoop, B.; van den Bosch, H.C.M.; Raat, F.; Witjes, J.Alfred.; Mulders, P.F.A.; van der Kaa, C.Hulsbergen.; Barentsz, J.O., 2009:
Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging

Puech, P.; Villers, A.; Ouzzane, A.; Lemaitre, L., 2015:
Prostate cancer: diagnosis, parametric imaging and standardized report

Oto, A.; Kayhan, A.; Jiang, Y.; Tretiakova, M.; Yang, C.; Antic, T.; Dahi, F.; Shalhav, A.L.; Karczmar, G.; Stadler, W.M., 2011:
Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging

Haghighi, M.; Shah, S.; Taneja, S.S.; Rosenkrantz, A.B., 2014:
Prostate cancer: diffusion-weighted imaging versus dynamic-contrast enhanced imaging for tumor localization-a meta-analysis

Abadi-Korek, I.; Shemer, J., 2013:
Prostate cancer: do patients understand what they choose?

Hennequin, C.; Rivera, S.; Quero, L.; Latorzeff, I., 2010:
Prostate cancer: doses and volumes of radiotherapy

Penson, D.F.; Rossignol, M.; Sartor, A.Oliver.; Scardino, P.T.; Abenhaim, L.L., 2009:
Prostate cancer: epidemiology and health-related quality of life

Reis, L.Oliveira.; Sasse, Aé.Deeke.; Matheus, W.Eduardo.; Denardi, F.; Stopiglia, R.Mamprim.; da Silva, Mício.Moreira.; Ferreira, U., 2009:
Prostate cancer: evidence based clinical practice

Azmi, A.; O'Neill, B., 2011:
Prostate cancer: evidence-based indications for postoperative radiotherapy

Vorob'ëv, A.V., 2009:
Prostate cancer: evolution of approach

Small, E.J.; de Bono, J.Sebastian., 2011:
Prostate cancer: evolution or revolution?

Rosenkrantz, A.B.; Sigmund, E.E.; Johnson, G.; Babb, J.S.; Mussi, T.C.; Melamed, J.; Taneja, S.S.; Lee, V.S.; Jensen, J.H., 2012:
Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer

Locke, J.A.; Bruchovsky, N., 2010:
Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy

Fizazi, K., 2008:
Prostate cancer: future strategies for chemotherapy management

Brown, M., 2010:
Prostate cancer: how assessment of QoL can improve delivery of care

Enel, C.; Matte, A.; Berchi, Célia.; Binquet, C.; Cormier, L.; Lejeune, C., 2013:
Prostate cancer: how do patients choose their treatment?

Mazaheri, Y.; Shukla-Dave, A.; Hricak, H.; Fine, S.W.; Zhang, J.; Inurrigarro, G.; Moskowitz, C.S.; Ishill, N.M.; Reuter, V.E.; Touijer, K.; Zakian, K.L.; Koutcher, J.A., 2008:
Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings

Kupelian, P.; Meyer, J.L., 2007 :
Prostate cancer: image guidance and adaptive therapy

Ploussard, G.; Desgrandchamps, Fçois., 2013:
Prostate cancer: interpretation of management guidelines

Kumar, R., 2013:
Prostate cancer: is it all just hype?

Chism, K.; Kunkel, E.J.S., 2009:
Prostate cancer: issues in psychosomatic medicine

Farooqi, A.Ahmad.; Qureshi, M.Zahid.; Rehman, A.; Nogueira, D.Rubert.; Awan, I.Iftikhar.; Shahid, A., 2014:
Prostate cancer: leading and misleading routes to TRAIL of death

Pezaro, C.; Woo, H.H.; Davis, I.D., 2015:
Prostate cancer: measuring PSA

Kanso, C.; Etner, J.; Debré, B.; Zerbib, M., 2010:
Prostate cancer: medicoeconomic aspects

Raghavan, D.; Klein, E.A., 2008:
Prostate cancer: moving forward by reinventing the wheel...but this time it is round

Salomon, L.; Descazeaud, A., 2008:
Prostate cancer: news in 2008

Kattan, M.W.; Scardino, P.T., 2013:
Prostate cancer: nomograms and risk assessment models

Herrmann, T.R.W.; Merseburger, A.S.; Burchardt, M., 2011:
Prostate cancer: novel aspects of diagnostics and surgical technology

Porche, D., 2011:
Prostate cancer: overview of screening, diagnosis and treatment

Thompson, J.C.; Wood, J.; Feuer, D., 2007:
Prostate cancer: palliative care and pain relief

Lawrence, E.M.; Tang, S.Y.W.; Barrett, T.; Koo, B.; Goldman, D.A.; Warren, A.Y.; Axell, R.G.; Doble, A.; Gallagher, F.A.; Gnanapragasam, V.J.; Kastner, C.; Sala, E., 2014:
Prostate cancer: performance characteristics of combined T₂W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion

Westphalen, A.C.; Koff, W.J.; Coakley, F.V.; Muglia, V.F.; Neuhaus, J.M.; Marcus, R.T.; Kurhanewicz, J.; Smith-Bindman, R., 2011:
Prostate cancer: prediction of biochemical failure after external-beam radiation therapy--Kattan nomogram and endorectal MR imaging estimation of tumor volume

Barboro, P.; Salvi, S.; Rubagotti, A.; Boccardo, S.; Spina, B.; Truini, M.; Carmignani, G.; Introini, C.; Ferrari, N.; Boccardo, F.; Balbi, C., 2014:
Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression

Ribeiro da Silva, M.N.; Tobias-Machado, M.; Lima-Pompeo, A.C.; Reis, L.O.; da Silva Pinhal, M.A., 2013:
Prostate cancer: promising biomarkers related to aggressive disease

Roth, A.J.; Weinberger, M.I.; Nelson, C.J., 2008:
Prostate cancer: psychosocial implications and management

Alberti, C., 2015:
Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization

Chi, B.Hoon.; Chang, I.Ho., 2010:
Prostate cancer: recent trends in Korea

Barry Delongchamps, N., 2015:
Prostate cancer: review in 2014

Beheshti, M.; Langsteger, W.; Fogelman, I., 2010:
Prostate cancer: role of SPECT and PET in imaging bone metastases

McKenna, D.A.; Coakley, F.V.; Westphalen, A.C.; Zhao, S.; Lu, Y.; Webb, E.M.; Pickett, B.; Roach, M.; Kurhanewicz, J., 2008:
Prostate cancer: role of pretreatment MR in predicting outcome after external-beam radiation therapy--initial experience

Park, J.Jae.; Kim, C.Kyo.; Park, S.Yoon.; Park, B.Kwan.; Lee, H.Moo.; Cho, S.Whi., 2014:
Prostate cancer: role of pretreatment multiparametric 3-T MRI in predicting biochemical recurrence after radical prostatectomy

Bates, S.E., 2011:
Prostate cancer: score one for validated targets

Grubb, R.L.; Kibel, A.S., 2007:
Prostate cancer: screening, diagnosis and management in 2007

Anonymous, 2012:
Prostate cancer: send away the PSA?

Weinreb, J.C.; Blume, J.D.; Coakley, F.V.; Wheeler, T.M.; Cormack, J.B.; Sotto, C.K.; Cho, H.; Kawashima, A.; Tempany-Afdhal, C.M.; Macura, K.J.; Rosen, M.; Gerst, S.R.; Kurhanewicz, J., 2009:
Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study

Testa, C.; Schiavina, R.; Lodi, R.; Salizzoni, E.; Corti, B.; Farsad, M.; Kurhanewicz, J.; Manferrari, F.; Brunocilla, E.; Tonon, C.; Monetti, N.; Castellucci, P.; Fanti, S.; Coe, M.; Grigioni, W.F.; Martorana, G.; Canini, R.; Barbiroli, B., 2007:
Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT

Das, S.; Zain, J.M., 2011:
Prostate cancer: some interesting facts

Graham, J.; Kirkbride, P.; Cann, K.; Hasler, E.; Prettyjohns, M., 2014:
Prostate cancer: summary of updated NICE guidance

Vieweg, J.W., 2008:
Prostate cancer: targeting complexity

Nau, J-Yves., 2014:
Prostate cancer: the French figures of excess screening and its complications

Hill, C.; Laplanche, Aès., 2010:
Prostate cancer: the evidence weighs against screening

Rouvière, O., 2011:
Prostate cancer: the importance of tumor mapping

Felgueiras, J.; Silva, J.Vieira.; Fardilha, M., 2014:
Prostate cancer: the need for biomarkers and new therapeutic targets

Moul, J.W.; Mouraviev, V.; Sun, L.; Schroeck, F.R.; Polascik, T.J., 2009:
Prostate cancer: the new landscape

Fernández-Serra, A.; Rubio-Briones, J.; García-Casado, Z.; Solsona, E.; López-Guerrero, J.A., 2011:
Prostate cancer: the revolution of the fusion genes

Lee, J.Z.; Singh, N.; Howe, C.L.; Low, S-Wei.; Huang, J.J.; Ortega, G.; Lee, K.S.; Pandit, A., 2018:
Colchicine for Prevention of Post-Operative Atrial Fibrillation: A Meta-Analysis

Shteynshlyuger, A.; Andriole, G.L., 2010:
Prostate cancer: to screen or not to screen?

Raghavan, D., 2008:
Prostate cancer: too much dogma, not enough data

Berney, D.; Cheng, L., 2012:
Prostate cancer: towards the standardization and synthesis of morphology, genetics, and prognosis

Tasso, M.; Varvello, F.; Ferrando, U., 2009:
Prostate cancer: transrectal high-intensity focused ultrasound for the treatment of local recurrence after radical prostatectomy or radiotherapy

Gomez-Veiga, F.; Pertega Diaz, S.; Martinez Breijo, S., 2014:
Prostate cancer: treat or not treat?

Cremers, R.G.H.M.; Karim-Kos, H.E.; Houterman, S.; Verhoeven, R.H.A.; Schröder, F.H.; van der Kwast, T.H.; Kil, P.J.M.; Coebergh, J.W.W.; Kiemeney, L.A.L.M., 2010:
Prostate cancer: trends in incidence, survival and mortality in the Netherlands, 1989-2006

Grosclaude, P., 2009:
Prostate cancer: update on screening

Rosenkrantz, A.B.; Mannelli, L.; Kong, X.; Niver, B.E.; Berkman, D.S.; Babb, J.S.; Melamed, J.; Taneja, S.S., 2011:
Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization

Turkbey, B.; Pinto, P.A.; Mani, H.; Bernardo, M.; Pang, Y.; McKinney, Y.L.; Khurana, K.; Ravizzini, G.C.; Albert, P.S.; Merino, M.J.; Choyke, P.L., 2010:
Prostate cancer: value of multiparametric MR imaging at 3 T for detection--histopathologic correlation

Zattoni, F., 2013:
Prostate cancer: what are the news in hormonal therapy? The role of GnRH antagonists

Burgess, E.F.; Raghavan, D., 2013:
Prostate cancer: what did we learn from the 2012 Annual Scientific Meeting of ASCO?

Nguyen, T.D.; Azria, D.; Brochon, D.; Poortmans, P.; Miller, R.C., 2009:
Prostate cancer: what role for curative radiotherapy in elderly?

de Crevoisier, R.; Castelli, J.; Guérif, S.; Pommier, P.; Créhange, G.; Chauvet, B.; Lagrange, J.L., 2014:
Prostate cancer: what treatment techniques for which tumors? Ethical and methodological issues

D'Amico, A.V., 2014:
Prostate cancer: where we have been, where we are, and where we are going

Anonymous, 2013:
Prostate cancer: who should be treated?

Augustin, H.; Auprich, M.; Mannweiler, S.; Pachernegg, O.; Al-Ali, B.Mohamad.; Pummer, K., 2012:
Prostate cancers detected by saturation repeat biopsy impairs the Partin tables' accuracy to predict final pathological stage

Lee, F.; Badalament, R.A.; Hu, C.; Bousho, I.; Tsodikov, A., 2012:
Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls

Eminaga, O.; Hinkelammert, R.; Abbas, M.; Titze, U.; Eltze, E.; Bettendorf, O.; Wötzel, F.; Bögemann, M.; Semjonow, A., 2015:
Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies

Tan, N.; Lane, B.R.; Li, J.; Moussa, A.S.; Soriano, M.; Jones, J.Stephen., 2008:
Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade

Klotz, L., 2009:
Prostate capsule sparing radical cystectomy: oncologic safety and clinical outcome

Jacobs, B.L.; Daignault, S.; Lee, C.T.; Hafez, K.S.; Montgomery, J.S.; Montie, J.E.; Humrich, J.E.; Hollenbeck, B.K.; Wood, D.P.; Weizer, A.Z., 2015:
Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial

Gonçalves, B.F.; Zanetoni, C.; Scarano, W.R.; Góes, R.M.; Vilamaior, P.S.L.; Taboga, São.R.; Campos, S.G.P., 2010:
Prostate carcinogenesis induced by N-methyl-N-nitrosourea (mnu) in gerbils: histopathological diagnosis and potential invasiveness mediated by extracellular matrix components

Hara, N., 2012:
Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update

Schlemmer, H-P., 2007:
Prostate carcinoma

Fitzgerald, T.J.; Wang, T.; Goel, H.Lal.; Huang, J.; Stein, G.; Lian, J.; Davis, R.J.; Doxsey, S.; Balaji, K.C.; Aronowitz, J.; Languino, L.R., 2008:
Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention

Rhoden, E.Luis.; Averbeck, Márcio.Augusto., 2010:
Prostate carcinoma and testosterone: risks and controversies

Donini, M.; Marongiu, L.; Fontana, E.; Dusi, S., 2012:
Prostate carcinoma cells LNCaP and glucan cooperate in induction of cytokine synthesis by dendritic cells: effect on natural killer cells and CD4+ lymphocytes activation

Bourdeau-Heller, J.; Oberley, T.D., 2007:
Prostate carcinoma cells selected by long-term exposure to reduced oxygen tension show remarkable biochemical plasticity via modulation of superoxide, HIF-1alpha levels, and energy metabolism

Ravaud, A.; Pasticier, G.; Davin, J-Louis.; Demeaux, Hélène.; Maire, J-Philippe., 2008:
Prostate carcinoma in the elderly

Alsuhaibani, A.H.; Carter, K.D.; Nerad, J.A.; Lee, A.G., 2008:
Prostate carcinoma metastasis to extraocular muscles

Onitilo, A.A.; Engel, J.M.; Resnick, J.M., 2010:
Prostate carcinoma metastatic to the stomach: report of two cases and review of the literature

Tan-Shalaby, J., 2014:
Prostate carcinoma presenting with bulky mediastinal and cervical lymphadenopathy

Liu, Z.; Leong, Q.; Teo, H.Yi.; Lee, Y.Mun., 2016:
Prostate carcinoma presenting with symptoms mimicking rectal cancer

Yan, W.; Li, H.; Zhou, Y.; Huang, Z.; Rong, S.; Xia, M.; Ji, Z.; Chen, J.; Jiang, Y., 2008:
Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy

Seven, B.; Varoglu, E.; Cayir, K.; Sahin, A.; Kantarci, M., 2008:
Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen

Nagashima, T.; Niiro, M.; Hirayama, K.; Date, S.; Okihara, K.; Mukaisho, K-Ichi., 2012:
Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report

Ruchalla, E., 2014:
Prostate carcinoma--18F-choline-PET/CT for relapse

Hanus, M.; Matoušková, M.; Dušek, L., 2015:
Prostate carcinoma. Current dilemma of urooncology. How to help the needed and not to harm the others

Mikuz, G.; Algaba, F.; Beltran, A.Lopez.; Montironi, R., 2007:
Prostate carcinoma: atrophy or not atrophy that is the question

Luboldt, W.; Küfer, R.; Blumstein, N.; Toussaint, T.L.; Kluge, A.; Seemann, M.D.; Luboldt, H-Joachim., 2008:
Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases

Bedke, J.; Gouttefangeas, C.; Stenzl, A., 2012:
Prostate carcinoma: vaccination as a new option for treatment

Johnson, I.R.; Parkinson-Lawrence, E.J.; Butler, L.M.; Brooks, D.A., 2014:
Prostate cell lines as models for biomarker discovery: performance of current markers and the search for new biomarkers

He, J.; Han, S.; Yang, F.; Zhou, N.; Wang, S., 2014:
Prostate cell membrane chromatography-liquid chromatography-mass spectrometry for screening of active constituents from Uncaria rhynchophylla

Mazzucchelli, R.; Lopez-Beltran, A.; Galosi, A.B.; Zizzi, A.; Scarpelli, M.; Bracarda, S.; Cheng, L.; Montironi, R., 2015:
Prostate changes related to therapy: with special reference to hormone therapy

Vikal, S.; Haker, S.; Tempany, C.; Fichtinger, G., 2009:
Prostate contouring in MRI guided biopsy

Khoo, E.L.H.; Schick, K.; Plank, A.W.; Poulsen, M.; Wong, W.W.G.; Middleton, M.; Martin, J.M., 2012:
Prostate contouring variation: can it be fixed?

Garber, B.B.; Tapscott, A.H., 2012:
Prostate cryoablation in patients with multiple-component inflatable penile prostheses

E.H.yek, O.R.; Alfer, W.; Reggio, E.; Pompeo, A.Carlos.L.; Arap, S.; Lucon, A.Marmo.; Srougi, M., 2008:
Prostate cryoablation: prospective analysis comparing high- and low-risk prostate cancer outcomes

Mitri, F.G.; Davis, B.J.; Alizad, A.; Greenleaf, J.F.; Wilson, T.M.; Mynderse, L.A.; Fatemi, M., 2008:
Prostate cryotherapy monitoring using vibroacoustography: preliminary results of an ex vivo study and technical feasibility

Ritch, C.R.; Katz, A.E., 2009:
Prostate cryotherapy: current status

Mosharafa, A.A.; Torky, M.H.; Ragab, Y.; Dahba, N., 2011:
Prostate cystadenoma presenting with obstructive azoospermia

Olsen, H.L.; Jakobsen, H.; Thomsen, R.W., 2013:
Prostate database for the treatment of benign prostatic hyperplasia

Rosewall, T.; Kong, V.; Vesprini, D.; Catton, C.; Chung, P.; Ménard, C.; Bayley, A., 2009:
Prostate delineation using CT and MRI for radiotherapy patients with bilateral hip prostheses

Mukhopadhyay, A.; Khoury, T.; Stein, L.; Shrikant, P.; Sood, A.K., 2013:
Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer

Thomson, A.A.; Cunha, G.R.; Marker, P.C., 2008:
Prostate development and pathogenesis

Timms, B.G., 2008:
Prostate development: a historical perspective

Galić, J.; Simunović, D., 2009:
Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia

Karunasinghe, N.; Han, D.Yeo.; Goudie, M.; Zhu, S.; Bishop, K.; Wang, A.; Duan, H.; Lange, K.; Ko, S.; Medhora, R.; Kan, S.Theng.; Masters, J.; Ferguson, L.R., 2013:
Prostate disease risk factors among a New Zealand cohort

Anunobi, C.C.; Akinde, O.R.; Elesha, S.O.; Daramola, A.O.; Tijani, K.H.; Ojewola, R.W., 2011:
Prostate diseases in Lagos, Nigeria: a histologic study with tPSA correlation

Welén, K.; Damber, J-Erik., 2011:
Prostate diseases--role of sex steroids and their inhibitors

Jorns, J.J.; Thiel, D.D.; Young, P.R.; Broderick, G.A., 2011:
Prostate diverticulum

Ciammella, P.; Galeandro, M.; D'Abbiero, N.; Palmieri, T.; Donini, E.; Iotti, C., 2014:
Prostate embryonal rhabdomyosarcoma in adults: Case report and review of literature

McNamara, K.M.; Nakamura, Y.; Sasano, H.; Handelsman, D.J.; Simanainen, U., 2013:
Prostate epithelial AR inactivation leads to increased intraprostatic androgen synthesis

Martin, P.; Liu, Y-Nien.; Pierce, R.; Abou-Kheir, W.; Casey, O.; Seng, V.; Camacho, D.; Simpson, R.Mark.; Kelly, K., 2011 :
Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition

Matusik, R.J.; Jin, R.Jie.; Sun, Q.; Wang, Y.; Yu, X.; Gupta, A.; Nandana, S.; Case, T.C.; Paul, M.; Mirosevich, J.; Oottamasathien, S.; Thomas, J., 2008:
Prostate epithelial cell fate

Kwon, O-Joon.; Xin, L., 2014:
Prostate epithelial stem and progenitor cells

Bajek, A.; Pokrywka, L.; Wolski, Z.; Dębski, R.; Drewa, T., 2011:
Prostate epithelial stem cells are resistant to apoptosis after α1-antagonist treatment. The impact for BPH patients

Luchman, H.Artee.; Villemaire, M.L.; Bismar, T.A.; Carlson, B.A.; Jirik, F.R., 2016:
Prostate epithelium-specific deletion of the selenocysteine tRNA gene Trsp leads to early onset intraepithelial neoplasia

Wada, Y.; Takahashi, W.; Latifpour, J.; Weiss, R.M.; Matsumoto, K.; Matsui, K.; Yamada, G.; Imamura, T., 2008:
Prostate expression of endothelins and their receptors in rat growth

Qi, X.; Han, L.; Liu, X.; Zhi, J.; Zhao, B.; Chen, D.; Yu, F.; Zhou, X., 2013:
Prostate extract with aluminum hydroxide injection as a novel animal model for chronic prostatitis/chronic pelvic pain syndrome

Foroudi, F.; Fox, C., 2008:
Prostate fiducials and margins

Niaf, E.; Lartizien, C.; Bratan, F.; Roche, L.; Rabilloud, M.; Mège-Lechevallier, F.; Rouvière, O., 2014:
Prostate focal peripheral zone lesions: characterization at multiparametric MR imaging--influence of a computer-aided diagnosis system

Newell, K.J.; Amrhein, J.F.; Desai, R.J.; Middlebrook, P.F.; Webster, T.M.; Sawka, B.W.; Rudrick, B.F., 2008 :
Prostate gland biopsies and prostatectomies: an Ontario community hospital experience

Fang, B.; Cho, F.; Lam, W., 2014:
Prostate gland development and adrenal tumor in a female with congenital adrenal hyperplasia: a case report and review from radiology perspective

Cury, F.L.; Duclos, M.; Aprikian, A.; Patrocinio, H.; Souhami, L., 2010:
Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy

Ahmad, I.; Kalna, G.; Ismail, M.; Birrell, F.; Asterling, S.; McCartney, E.; Greene, D.; Davies, J.; Leung, H.Y., 2014:
Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer

Pavelić, J.; Zeljko, Z., 2009:
Prostate gland-transition zone lesions. Etiology, growth regulation, growth factors, genetic changes

Kojima, Y.; Sasaki, S.; Oda, N.; Koshimizu, T-Aki.; Hayashi, Y.; Kiniwa, M.; Tsujimoto, G.; Kohri, K., 2009:
Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia

Liu, Y.; Xu, Y.; Zhang, Z-Hong.; Yang, K., 2015:
Prostate health index in predicting the results of prostate biopsy for prostate cancer: a meta-analysis

Bruzzese, D.; Mazzarella, C.; Ferro, M.; Perdonà, S.; Chiodini, P.; Perruolo, G.; Terracciano, D., 2015:
Prostate health index vs percent free prostate-specific antigen for prostate cancer detection in men with "gray" prostate-specific antigen levels at first biopsy: systematic review and meta-analysis

Porche, D.J., 2009:
Prostate health: definitely a men's health issue

Anonymous, 2014:
Prostate help: a test that can help you avoid unnecessary prostate biopsies. When you've already had a biopsy and your PSA remains high, the PCA3 urine test can help you and your doctor to decide if another biopsy is really needed

Tharp, M.; Hardacre, M.; Bennett, R.; Jones, W.Terry.; Stuhldreher, D.; Vaught, J., 2008:
Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer

Gorelick, L.; Veksler, O.; Gaed, M.; Gomez, J.A.; Moussa, M.; Bauman, G.; Fenster, A.; Ward, A.D., 2014:
Prostate histopathology: learning tissue component histograms for cancer detection and classification

Macek, P.; Barret, E.; Sanchez-Salas, R.; Galiano, M.; Rozet, F.; Ahallal, Y.; Gaya, J.M.; Durant, M.; Mascle, L.; Giedelman, C.; Lunelli, L.; Validire, P.; Nesvadba, M.; Cathelineau, X., 2014:
Prostate histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study

Wheat, J.C.; Hall, T.L.; Hempel, C.R.; Cain, C.A.; Xu, Z.; Roberts, W.W., 2010:
Prostate histotripsy in an anticoagulated model

Schade, G.R.; Styn, N.R.; Ives, K.A.; Hall, T.L.; Roberts, W.W., 2014:
Prostate histotripsy: evaluation of prostatic urethral treatment parameters in a canine model

Zucca, S.; Carau, B.; Solla, I.; Garibaldi, E.; Farace, P.; Lay, G.; Meleddu, G.; Gabriele, P., 2011:
Prostate image-guided radiotherapy by megavolt cone-beam CT

Dusing, R.W.; Drisko, J.A.; Grado, G.G.; Levine, M.; Holzbeierlein, J.M.; Van Veldhuizen, P., 2011:
Prostate imaging modalities that can be used for complementary and alternative medicine clinical studies

Westphalen, A.C.; Rosenkrantz, A.B., 2014:
Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI

Chun, F.K-H.; Herrmann, T.R.W., 2015:
Prostate imaging--the future is now: current concepts and future potentials

Haider, M.A.; Krieger, A.; Elliott, C.; D.R.sa, M.R.; Milot, L., 2014:
Prostate imaging: evaluation of a reusable two-channel endorectal receiver coil for MR imaging at 1.5 T

Karan, D., 2014:
Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?

Dehghan, E.; Moradi, M.; Wen, X.; French, D.; Lobo, J.; Morris, W.James.; Salcudean, S.E.; Fichtinger, G., 2011:
Prostate implant reconstruction from C-arm images with motion-compensated tomosynthesis

Liu, X.; Jain, A.K.; Fichtinger, G., 2007:
Prostate implant reconstruction with discrete tomography

Abdel-Meguid, T.A.; Mosli, H.A.; Al-Maghrabi, J.A., 2010:
Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer

Adamson, J.; Wu, Q., 2010:
Prostate intrafraction motion assessed by simultaneous kV fluoroscopy at MV delivery II: adaptive strategies

Adamson, J.; Wu, Q., 2010:
Prostate intrafraction motion assessed by simultaneous kilovoltage fluoroscopy at megavoltage delivery I: clinical observations and pattern analysis

Adamson, J.; Wu, Q., 2008:
Prostate intrafraction motion evaluation using kV fluoroscopy during treatment delivery: a feasibility and accuracy study

Litzenberg, D.W.; Balter, J.M.; Hadley, S.W.; Hamstra, D.A.; Willoughby, T.R.; Kupelian, P.A.; Djemil, T.; Mahadevan, A.; Jani, S.; Weinstein, G.; Solberg, T.; Enke, C.; Levine, L.; Sandler, H.M., 2011:
Prostate intrafraction translation margins for real-time monitoring and correction strategies

Bouabdallah, Z.; Kharbouchi, A.; Colau, A.; Cariou, G., 2014:
Prostate laser photovaporisation in patients at high risk of bleeding

Woldrich, J.M.; Palazzi-Churas, K.; Lakin, C.; Albo, M.; Parsons, J.Kellogg., 2011:
Prostate laser vaporization in men with urinary retention

Dema, A.; Borda, A.; Lazăr, E.; Lăzureanu, Cţa.; Tăban, S.; Anderco, D.; Cornianu, Mărioara.; Mureşan, A.; Herman, D.; Loghin, A.; Cornea, R.; Faur, A., 2011:
Prostate lesions with cribriform / pseudocribriform pattern

Kim, J.; Hammoud, R.; Pradhan, D.; Zhong, H.; Jin, R.Y.; Movsas, B.; Chetty, I.J., 2010:
Prostate localization on daily cone-beam computed tomography images: accuracy assessment of similarity metrics

Roethke, M.C.; Kuru, T.H.; Radbruch, A.; Hadaschik, B.; Schlemmer, H-Peter., 2013:
Prostate magnetic resonance imaging at 3 Tesla: Is administration of hyoscine-N-butyl-bromide mandatory?

Loch, R.; Fowler, K.; Schmidt, R.; Ippolito, J.; Siegel, C.; Narra, V., 2015:
Prostate magnetic resonance imaging: challenges of implementation

Storås, T.H.; Gjesdal, K-Inge.; Gadmar, Øystein.B.; Geitung, J.T.; Kløw, N-Einar., 2008:
Prostate magnetic resonance imaging: multiexponential T2 decay in prostate tissue

Klock, Cóvis.; Gomes, R.; João, M.; Netto, G., 2011:
Prostate melanosis associated with acinar adenocarcinoma

Balaban, M.; Selimoglu, A.; Horuz, R.; Akca, O.; Albayrak, S., 2013:
Prostate metastasis of malignant melanoma

Guler, O.Cem.; Onal, C.; Erbay, G.; Bal, N., 2014:
Prostate mucinous carcinoma treated with definitive radiotherapy and hormonal therapy: case report and review of the literature

Daar, D.; Bernardo, M.; Choyke, P.L.; McKinney, Y.; Turkbey, B., 2011:
Prostate multiparameter MR imaging

Berg, K.Drimer.; Toft, B.Grønkaer.; Røder, M.Andreas.; Brasso, K.; Vainer, B.; Iversen, P., 2011:
Prostate needle biopsies: interobserver variation and clinical consequences of histopathological re-evaluation

Chargari, C.; Comperat, E.; Magné, N.; Védrine, L.; Houlgatte, A.; Egevad, L.; Camparo, P., 2011:
Prostate needle biopsy examination by means of virtual microscopy

Varma, M.; Berney, D.M.; Algaba, F.; Camparo, P.; Compérat, E.; Griffiths, D.F.R.; Kristiansen, G.; Lopez-Beltran, A.; Montironi, R.; Egevad, L., 2013:
Prostate needle biopsy processing: a survey of laboratory practice across Europe

Bostwick, D.G.; Qian, J.; Drewnowska, K.; Varvel, S.; Bostwick, K.C.; Marberger, M.; Rittmaster, R.S., 2010:
Prostate needle biopsy quality in reduction by dutasteride of prostate cancer events study: worldwide comparison of improvement with investigator training and centralized laboratory processing

Fraggetta, F.; Pepe, P.; Improta, G.; Aragona, F.; Colecchia, M., 2014:
Prostate needle biopsy: what we do and what should be improved

Iczkowski, K.A., 2015:
Prostate pointers and pitfalls: the 10 most prevalent problems in prostate biopsy interpretation

Ryan, D.; Rivest, C.; Riauka, T.A.; Murtha, A.D.; Fallone, B.Gino., 2010:
Prostate positioning errors associated with two automatic registration based image guidance strategies

Jereczek-Fossa, B.A.; Pobbiati, C.; Santoro, L.; Fodor, C.; Fanti, P.; Vigorito, S.; Baroni, G.; Zerini, D.; D.C.belli, O.; Orecchia, R., 2014:
Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration: interobserver agreement between radiation oncologists and therapists

Beaulieu, L.; Verhaegen, F., 2008:
Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience: in regard to BLOCH et al. (Int J Radiat Oncol Biol Phys 2007;69:70-78)

Shi, X.; Gipp, J.; Dries, M.; Bushman, W., 2015:
Prostate progenitor cells proliferate in response to castration

Marinello, G.; Mege, J-P.; Besse, M-C.; Kerneur, G.; Lagrange, J-L., 2009:
Prostate radiation therapy: in vivo measurement of the dose delivered by kV-CBCT

Catton, C.; Parker, C.; Saad, F.; Sydes, M., 2010:
Prostate radiotherapy after radical prostatectomy: sooner or later?

Martin, J.; Frantzis, J.; Chung, P.; Langah, I.; Crain, M.; Cornes, D.; Plank, A.; Finch, T.; Jones, M.; Khoo, E.; Catton, C., 2014:
Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (A TROG-OCOG Intergroup Project)

Parker, C.C.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Aebersold, D.; de Bono, J.S.; Dearnaley, D.P.; Ritchie, A.W.S.; Russell, J.M.; Thalmann, G.; Parmar, M.K.B.; James, N.D., 2013:
Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial

Parker, C.C.; Sydes, M.R.; Mason, M.D.; Clarke, N.W.; Aebersold, D.; de Bono, J.S.; Dearnaley, D.P.; Ritchie, A.W.S.; Russell, J.Martin.; Thalmann, G.; Parmar, M.K.B.; James, N.D., 2013:
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial

Swan, R.H., 1923:
Prostate removed by Prostatectomy; Weight, 12 oz., or 340 grm

Shang, Q.; Sheplan Olsen, L.J.; Stephans, K.; Tendulkar, R.; Xia, P., 2013:
Prostate rotation detected from implanted markers can affect dose coverage and cannot be simply dismissed

Iremashvili, V.; Pelaez, L.; Jorda, M.; Manoharan, M.; Arianayagam, M.; Rosenberg, D.L.; Soloway, M.S., 2012:
Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens

Busto Martín, L.; Carral Freire, M.; Hermida, T.; Aller, M.; Busto Castañón, L., 2014:
Prostate sarcoma: report of 2 cases and bibliographic review

Ashish, K.; Bandyopadhyay, D.; Mondal, S.; Ghosh, R.Kumar., 2018:
Colchicine in coronary artery disease: Role of anti-inflammatory medications redefined

Maccagnano, C.; Gallina, A.; Roscigno, M.; Raber, M.; Capitanio, U.; Saccà, A.; Pellucchi, F.; Suardi, N.; Abdollah, F.; Montorsi, F.; Rigatti, P.; Scattoni, V., 2013:
Prostate saturation biopsy following a first negative biopsy: state of the art

Salmasi, A.Hassanzadeh.; Wisniewski, A.B.; Novak, T.E.; Gearhart, J.P.; Migeon, C.J.; Lakshmanan, Y., 2008:
Prostate screening in patients with 46,XY disorders of sex development--is it necessary?

McKinley, J.M.; Weideman, P.C.; Jenkins, M.A.; Friedlander, M.L.; Hopper, J.L.; McLachlan, S-Anne.; Lindeman, G.J.; Phillips, K-Anne., 2007:
Prostate screening uptake in Australian BRCA1 and BRCA2 carriers

Hawkes, N., 2010:
Prostate screening: is the tide turning against the test?

Thumbikat, P.; Shahrara, S.; Sobkoviak, R.; Done, J.; Pope, R.M.; Schaeffer, A.J., 2010:
Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators

Wu, Y.; Liu, G.; Huang, M.; Guo, J.; Jiang, J.; Yang, W.; Chen, W.; Feng, Q., 2015:
Prostate segmentation based on variant scale patch and local independent projection

Gao, Y.; Liao, S.; Shen, D., 2013:
Prostate segmentation by sparse representation based classification

Garnier, C.; Bellanger, J-Jacques.; Wu, K.; Shu, H.; Costet, N.; Mathieu, R.; de Crevoisier, R.; Coatrieux, J-Louis., 2011:
Prostate segmentation in HIFU therapy

Yang, M.; Li, X.; Turkbey, B.; Choyke, P.L.; Yan, P., 2013:
Prostate segmentation in MR images using discriminant boundary features

Qiu, W.; Yuan, J.; Ukwatta, E.; Sun, Y.; Rajchl, M.; Fenster, A., 2014:
Prostate segmentation: an efficient convex optimization approach with axial symmetry using 3-D TRUS and MR images

Hong, S.Kyu.; Poon, B.Ying.; Sjoberg, D.D.; Scardino, P.T.; Eastham, J.A., 2014:
Prostate size and adverse pathologic features in men undergoing radical prostatectomy

Davies, J.D.; Aghazadeh, M.A.; Phillips, S.; Salem, S.; Chang, S.S.; Clark, P.E.; Cookson, M.S.; Davis, R.; Herrell, S.Duke.; Penson, D.F.; Smith, J.A.; Barocas, D.A., 2012:
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer

Kim, W.Tae.; Yun, S.Joong.; Choi, Y.Deuk.; Kim, G-Young.; Moon, S-Kwon.; Choi, Y.Hyun.; Kim, I.Yi.; Kim, W-Jae., 2012:
Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels

Ngo, T.C.; Conti, S.L.; Shinghal, R.; Presti, J.C., 2012:
Prostate size does not predict high grade cancer

Pettus, J.A.; Masterson, T.; Sokol, A.; Cronin, A.M.; Savage, C.; Sandhu, J.S.; Mulhall, J.P.; Scardino, P.T.; Rabbani, F., 2009:
Prostate size is associated with surgical difficulty but not functional outcome at 1 year after radical prostatectomy

Ward, N.T.; Parsons, J.Kellogg.; Levinson, A.W.; Bagga, H.S.; Mettee, L.Z.; Su, L-Ming.; Pavlovich, C.P., 2011:
Prostate size is not associated with recovery of sexual function after minimally invasive radical prostatectomy

Yildirim, Y.; Akcay, Y.; Ozyilkan, O.; Celasun, B., 2008:
Prostate small cell carcinoma and skin metastases: a rare entity

Mertens, L.S.; Meijer, R.P.; de Vries, R.R.; Nieuwenhuijzen, J.A.; van der Poel, H.G.; Bex, A.; van Rhijn, B.W.G.; Meinhardt, W.; Horenblas, S., 2014:
Prostate sparing cystectomy for bladder cancer: 20-year single center experience

Radowicki, Sław.; Kunicki, Mł.; Wierzba, W., 2007:
Prostate specfic antigen in serum of healthy women

Sartor, O., 2008:
Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies

Suzuki, H.; Flanigan, R.C.; Okuyama, A., 2008:
Prostate specific antigen (PSA)-based screening

Mahar, P.; Sengupta, S.; Ludlow, K.; Corcoran, N., 2010:
Prostate specific antigen - useful screening tool or potential liability?

Anderson-Jackson, L.; McGrowder, D.A.; Alexander-Lindo, R., 2013:
Prostate specific antigen and Gleason score in men with prostate cancer at a private diagnostic radiology centre in Western Jamaica

Cansino, J.R.; Vera, R.; Rodríguez de Bethencourt, F.; Bouraoui, Y.; Rodríguez, G.; Prieto, A.; de la Peña, J.; Paniagua, R.; Royuela, M., 2011:
Prostate specific antigen and NF-kB in prostatic disease: relation with malignancy

Wiwanitkit, V., 2010:
Prostate specific antigen and mastopathy

Loeb, S.; Chan, D.W.; Sokoll, L.; Kan, D.; Maggiore, J.; Mikolajczyk, S.D.; Mondo, D.M.; Griffin, C.R.; Catalona, W.J., 2008:
Prostate specific antigen assay standardization bias could affect clinical decision making

Loeb, S.; Makarov, D.V.; Schaeffer, E.M.; Humphreys, E.B.; Walsh, P.C., 2010:
Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy

Greene, K.L.; Albertsen, P.C.; Babaian, R.J.; Carter, H.Ballentine.; Gann, P.H.; Han, M.; Kuban, D.Ann.; Sartor, A.Oliver.; Stanford, J.L.; Zietman, A.; Carroll, P., 2013:
Prostate specific antigen best practice statement: 2009 update

Wang, Y.; Brunsen, A.; Jonas, U.; Dostálek, J.; Knoll, W., 2010:
Prostate specific antigen biosensor based on long range surface plasmon-enhanced fluorescence spectroscopy and dextran hydrogel binding matrix

Hinnen, K.A.; Monninkhof, E.M.; Battermann, J.J.; van Roermund, J.G.H.; Frank, S.J.; van Vulpen, M., 2012:
Prostate specific antigen bounce is related to overall survival in prostate brachytherapy

Chaiyasit, K.; Wiwanitkit, V., 2014:
Prostate specific antigen change after administration of nimotuzumab in prostate cancer

Vickers, A.J.; Cronin, A.M.; Björk, T.; Manjer, J.; Nilsson, P.M.; Dahlin, A.; Bjartell, A.; Scardino, P.T.; Ulmert, D.; Lilja, H., 2010:
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study

Stopiglia, R.M.; Ferreira, U.; Silva, M.M.; Matheus, W.E.; Denardi, F.; Reis, L.O., 2010:
Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial

Oliveira-Reis, L., 2013:
Prostate specific antigen decrease and prostate cancer diagnosis: recognizing the fundamental previous progresses and moving forward

Lodeta, B.; Benko, G.; Car, S.; Filipan, Z.; Stajcar, D.; Dujmović, Tći., 2010:
Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml

Magheli, A.; Hinz, S.; Hege, C.; Stephan, C.; Jung, K.; Miller, K.; Lein, M., 2010:
Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience

Wang, X.; Zhao, M.; Nolte, D.D.; Ratliff, T.L., 2011:
Prostate specific antigen detection in patient sera by fluorescence-free BioCD protein array

Huang, Y.; Wang, T-Hong.; Jiang, J-Hui.; Shen, G-Li.; Yu, R-Qin., 2009:
Prostate specific antigen detection using microgapped electrode array immunosensor with enzymatic silver deposition

Ilic, D.; Green, S., 2009:
Prostate specific antigen for detecting early prostate cancer

Holmström, B.; Johansson, M.; Bergh, A.; Stenman, U-Håkan.; Hallmans, Göran.; Stattin, Pär., 2009:
Prostate specific antigen for early detection of prostate cancer: longitudinal study

Tsui, K-Hung.; Feng, T-Hsia.; Chung, L-Chuan.; Chao, C-Hsiang.; Chang, P-Lang.; Juang, H-Heng., 2008:
Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line

Park, Y.Hyun.; Hwang, I.Sik.; Jeong, C.Wook.; Kim, H.Hoe.; Lee, S.Eun.; Kwak, C., 2009:
Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer

Malati, T.; Kumari, G.Rajani.; Murthy, P.V.L.N.; Reddy, C.Ram.; Prakash, B.Surya., 2006:
Prostate specific antigen in patients of benign prostate hypertrophy and carcinoma prostate

Michał, K.; Stanisław, R., 2010:
Prostate specific antigen in women

Radowicki, S.; Kunicki, M., 2010:
Prostate specific antigen in women with menstrual disturbances and fibrocystic mastopathy

Açıkgöz, Şerefden.; Can, M.; Doğan, S.Mesut.; Mungan, Görkem.; Aydın, M.; Kelek, S.; Sümbüloğlu, V., 2012:
Prostate specific antigen levels after acute myocardial infarction

Chen, C.J.; Heldt, J.P.; Anderson, K.M.; Ruckle, H.C.; Agarwal, G.; Smith, D.L.; Schlaifer, A.E.; Richards, G.D.; Arnold, D.C.; Baldwin, D.Duane., 2013:
Prostate specific antigen levels and prostate cancer detection rates in patients with end stage renal disease

Fonseca, R.C.; Gomes, C.M.; Meireles, E.B.; Freire, G.C.; Srougi, M., 2008:
Prostate specific antigen levels following transurethral resection of the prostate

Hussain, S.; Abbas, G., 2010:
Prostate specific antigen levels in pre-dialysis chronic kidney disease patients

Choi, H-Chun.; Park, J-Ho.; Cho, B-Long.; Son, K-Young.; Kwon, H-Tae., 2010:
Prostate specific antigen mass ratio potential as a prostate cancer screening tool

Kinoshita, H.; Kamoto, T.; Nishiyama, H.; Nakamura, E.; Matsuda, T.; Ogawa, O., 2007:
Prostate specific antigen nadir determined using ultra-sensitive prostate specific antigen as a predictor of biochemical progression after radical prostatectomy in Japanese males

Mener, D.J., 2010:
Prostate specific antigen reduction following statin therapy: Mechanism of action and review of the literature

Block, K.I., 2009:
Prostate specific antigen screening

Konety, B.R., 2009:
Prostate specific antigen screening and active surveillance in the elderly

Tasian, G.E.; Cooperberg, M.R.; Cowan, J.E.; Keyashian, K.; Greene, K.L.; Daniels, N.A.; Carroll, P.R.; Chan, J.M., 2012:
Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians

Schaeffer, E.M.; Carter, H.Ballentine.; Kettermann, A.; Loeb, S.; Ferrucci, L.; Landis, P.; Trock, B.J.; Metter, E.Jeffrey., 2009:
Prostate specific antigen testing among the elderly--when to stop?

McKenzie, P.; Delahunt, B.; deVoss, K.; Ross, B.; Tran, H.; Sikaris, K., 2011:
Prostate specific antigen testing for the diagnosis of prostate cancer

Carey, M.; Bryant, J.; Yoong, S.Lin.; Russell, G.; Barker, D.; Sanson-Fisher, R., 2014:
Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure

Flahavan, E.M.; Drummond, F.J.; Bennett, K.; Barron, T.I.; Sharp, L., 2015:
Prostate specific antigen testing is associated with men's psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study

Van der Meer, S.; Löwik, S.A.M.; Hirdes, W.H.; Nijman, R.M.; Van der Meer, K.; Hoekstra-Weebers, J.E.H.M.; Blanker, M.H., 2013:
Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review

McKenzie, P.R.; Delahunt, B.; Kench, J.G.; Ross, B.; Lam, Q.; deVoss, K.; Tran, H.A.; Sikaris, K.A., 2013:
Prostate specific antigen testing: age-related interpretation in early prostate cancer detection

Kouriefs, C.; Sahoyl, M.; Grange, P.; Muir, G., 2010:
Prostate specific antigen through the years

Vickers, A.J.; Wolters, T.; Savage, C.J.; Cronin, A.M.; O'Brien, M.Frank.; Roobol, M.J.; Aus, G.; Scardino, P.T.; Hugosson, J.; Schröder, F.H.; Lilja, H., 2010:
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy

Choi, S.Young.; Chang, I.Ho.; Kim, Y.Sun.; Kim, T-Hyoung.; Kim, W.; Myung, S.Chul., 2011:
Prostate specific antigen velocity per prostate volume: a novel tool for prostate biopsy prediction

Patel, H.D.; Feng, Z.; Landis, P.; Trock, B.J.; Epstein, J.I.; Carter, H.Ballentine., 2014:
Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer

Moon, T.D., 2009:
Prostate specific antigen, pelvic pain and prostatitis--time for a new paradigm?

Radowicki, Sław.; Kunicki, Mł., 2010:
Prostate specific antigen--PSA and histopathological findings of endometrium in women with fibrocystic breast disease

Duskova, K.; Vesely, S., 2016:
Prostate specific antigen. Current clinical application and future prospects

Braillon, A., 2009:
Prostate specific antigen. Prostate screening in France

Gill, H.; Wu, J., 2013:
Prostate specific antigen: the past, present and future

Hannoun-Levi, J-M.; Ginot, A.; Thariat, J., 2009:
Prostate specific antigen: utilization modalities and interpretation

Nomura, N.; Pastorino, S.; Jiang, P.; Lambert, G.; Crawford, J.R.; Gymnopoulos, M.; Piccioni, D.; Juarez, T.; Pingle, S.C.; Makale, M.; Kesari, S., 2014:
Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases

Grant, C.L.; Caromile, L.A.; Ho, V.; Durrani, K.; Rahman, M.Mamunur.; Claffey, K.P.; Fong, G-Hua.; Shapiro, L.H., 2013:
Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization

Guo, Z.; Lai, Y.; Du, T.; Zhang, Y.; Chen, J.; Bi, L.; Lin, T.; Liu, H.; Wang, W.; Xu, K.; Jiang, C.; Han, J.; Zhang, C.; Dong, W.; Huang, J.; Huang, H., 2015:
Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway

Joung, J.Young.; Cho, K.Su.; Chung, H.Soo.; Cho, I-Chang.; Kim, J.Eun.; Seo, H.Kyung.; Chung, J.; Park, W.Seo.; Choi, M.Kyung.; Lee, K.Hyun., 2010:
Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy

Bouchelouche, K.; Choyke, P.L.; Capala, J., 2010:
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides

Bargão Santos, P.; Patel, H.Rh., 2014:
Prostate stem cell antigen - novel biomarker and therapeutic target?

Yang, X.; Guo, Z.; Liu, Y.; Si, T.; Yu, H.; Li, B.; Tian, W., 2014:
Prostate stem cell antigen and cancer risk, mechanisms and therapeutic implications

Wu, H.; Shi, H.; Zhang, H.; Wang, X.; Yang, Y.; Yu, C.; Hao, C.; Du, J.; Hu, H.; Yang, S., 2014:
Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery

Wang, D.; Wang, Z.; Tian, J.; He, X.; Chowdhury, W.H.; Zhang, X.; Li, S.; Rodriguez, R., 2008:
Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector

Ono, H.; Yanagihara, K.; Sakamoto, H.; Yoshida, T.; Saeki, N., 2012:
Prostate stem cell antigen gene is expressed in islets of pancreas

Hruska, M.; Keefe, J.; Wert, D.; Tekinay, A.Begum.; Hulce, J.J.; Ibañez-Tallon, I.; Nishi, R., 2010:
Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons

Zhao, Z.; Liu, J.; Li, S.; Shen, W., 2009:
Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia

Joung, J.Young.; Cho, K.Su.; Kim, J.Eun.; Seo, H.Kyung.; Chung, J.; Park, W.Seo.; Choi, M.Kyong.; Lee, K.Hyun., 2010:
Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high-risk prostate cancer

Wang, T.; Zhang, L.; Li, H.; Wang, B.; Chen, K., 2012:
Prostate stem cell antigen polymorphisms and susceptibility to gastric cancer: a systematic review and meta-analysis

Zhao, Y.; Gui, Z.L.; Liao, S.; Gao, F.; Ge, Y.Z.; Jia, R.P., 2015:
Prostate stem cell antigen rs2294008 (C>T) polymorphism and bladder cancer risk: a meta-analysis based on cases and controls

Zhao, J.; Geng, P.; Li, Z.; Cui, S.; Zhao, J.; Wang, L.; Li, J.; Ji, F.; Li, G.; Shen, G.; Lin, M.; Shen, C., 2014:
Prostate stem cell antigen rs2294008 polymorphism differentially contributes to iHelicobacter pylori -negative gastric cancer among various populations in China

Kim, S-Young.; Yoo, J-Young.; Shin, A.; Kim, Y.; Lee, E-Sook.; Lee, Y-Su., 2012:
Prostate stem cell antigen single nucleotide polymorphisms influence risk of estrogen receptor negative breast cancer in Korean females

Ono, H.; Hiraoka, N.; Lee, Y-Su.; Woo, S.Myung.; Lee, W.Jin.; Choi, I.Ju.; Saito, A.; Yanagihara, K.; Kanai, Y.; Ohnami, S.; Chiwaki, F.; Sasaki, H.; Sakamoto, H.; Yoshida, T.; Saeki, N., 2012:
Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis

Gao, X.; Luo, Y.; Wang, Y.; Pang, J.; Liao, C.; Lu, H.; Fang, Y., 2013:
Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy

Saeki, N.; Gu, J.; Yoshida, T.; Wu, X., 2010:
Prostate stem cell antigen: a Jekyll and Hyde molecule?

Prajapati, A.; Gupta, S.; Mistry, B.; Gupta, S., 2014:
Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts

Han, G-Wei.; Yi, S-Hong., 2015:
Prostate stem cells: an update

Takao, T.; Tsujimura, A., 2008:
Prostate stem cells: the niche and cell markers

Sala, Núria.; Muñoz, X.; Travier, N.; Agudo, A.; Duell, E.J.; Moreno, Víctor.; Overvad, K.; Tjonneland, A.; Boutron-Ruault, M.Christine.; Clavel-Chapelon, Fçoise.; Canzian, F.; Kaaks, R.; Boeing, H.; Meidtner, K.; Trichopoulos, A.; Tsiotas, K.; Zylis, D.; Vineis, P.; Panico, S.; Palli, D.; Krogh, V.; Tumino, R.; Lund, E.; Bueno-de-Mesquita, H.Bas.; Numans, M.E.; Peeters, P.H.M.; Quirós, J.Ramon.; Sánchez, Mía-José.; Navarro, C.; Ardanaz, E.; Dorronsoro, M.; Hallmans, Göran.; Stenling, R, 2012:
Prostate stem-cell antigen gene is associated with diffuse and intestinal gastric cancer in Caucasians: results from the EPIC-EURGAST study

Skydsgaard Schou-Jensen, K.; Dahl, C.; Azawi, N.Htum., 2015:
Prostate stent is an option for selected patients who are unsuitable for transurethral resection of the prostate

Murray, L.J.; Lilley, J.; Thompson, C.M.; Cosgrove, V.; Mason, J.; Sykes, J.; Franks, K.; Sebag-Montefiore, D.; Henry, A.M., 2014:
Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions

Tree, A.; Jones, C.; Sohaib, A.; Khoo, V.; van As, N., 2015:
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?

Tree, A.C.; Ostler, P.; Hoskin, P.; Dankulchai, P.; Nariyangadu, P.; Hughes, R.J.; Wells, E.; Taylor, H.; Khoo, V.S.; van As, N.J., 2015:
Prostate stereotactic body radiotherapy—first UK experience

Shaw, A.; Attia, S.; Bushman, W., 2008:
Prostate stromal and urogenital sinus mesenchymal cell lines for investigations of stromal-epithelial interactions

Yu, Y.; Lee, J.Suehyun.; Xie, N.; Li, E.; Hurtado-Coll, A.; Fazli, L.; Cox, M.; Plymate, S.; Gleave, M.; Dong, X., 2015:
Prostate stromal cells express the progesterone receptor to control cancer cell mobility

Kogan-Sakin, I.; Cohen, M.; Paland, N.; Madar, S.; Solomon, H.; Molchadsky, A.; Brosh, R.; Buganim, Y.; Goldfinger, N.; Klocker, H.; Schalken, J.A.; Rotter, V., 2009:
Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1

Cai, T.; Abrams, P.; Geppetti, P.; Bartoletti, R., 2010:
Prostate surgery to improve sleep quality: the key to success? (Related to: Hernández C. et al. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH). Curr Med Res Opin 2008 Apr;24(4):1033-8)

Bründl, J.; Zengerling, F.; Borgmann, H.; Syring, I., 2014:
Prostate surgery within residency programs in urology

Shoji, S.; Uchida, T.; Nakamoto, M.; Kim, H.; de Castro Abreu, A.Luis.; Leslie, S.; Sato, Y.; Gill, I.S.; Ukimura, O., 2013:
Prostate swelling and shift during high intensity focused ultrasound: implication for targeted focal therapy

Pareek, G.; Acharya, U.Rajendra.; Sree, S.Vinitha.; Swapna, G.; Yantri, R.; Martis, R.Joy.; Saba, L.; Krishnamurthi, G.; Mallarini, G.; El-Baz, A.; A.E.ish, S.; Beland, M.; Suri, J.S., 2014:
Prostate tissue characterization/classification in 144 patient population using wavelet and higher order spectra features from transrectal ultrasound images

Langer, D.L.; van der Kwast, T.H.; Evans, A.J.; Plotkin, A.; Trachtenberg, J.; Wilson, B.C.; Haider, M.A., 2010:
Prostate tissue composition and MR measurements: investigating the relationships between ADC, T2, K(trans), v(e), and corresponding histologic features

Neslund-Dudas, C.; Kandegedara, A.; Kryvenko, O.N.; Gupta, N.; Rogers, C.; Rybicki, B.A.; Dou, Q.Ping.; Mitra, B., 2014:
Prostate tissue metal levels and prostate cancer recurrence in smokers

Mohamed, S.S.; Li, J.; Salama, M.M.A.; Freeman, G., 2008:
Prostate tissue texture feature extraction for suspicious regions identification on TRUS images

Kilicaslan, I.; Gulluoglu, M.; Ozluk, Y.; Onat, E.; Cakir, E., 2011:
Prostate tissue within teratoma component of malignant mixed germ cell tumor

Billis, A.; Meirelles, L.R.; Freitas, L.L.L.; Polidoro, A.S.; Fernandes, H.A.; Padilha, M.M.; Magna, L.A.; Ferreira, U., 2013:
Prostate total tumor extent versus index tumor extent--which is predictive of biochemical recurrence following radical prostatectomy?

Jiang, W.G.; Ye, L.; Sanders, A.J.; Ruge, F.; Kynaston, H.G.; Ablin, R.J.; Mason, M.D., 2014:
Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain

Jiang, W.G.; Ablin, R.J., 2011:
Prostate transglutaminase: a unique transglutaminase and its role in prostate cancer

Lee, J.; McKinney, M.; Evans, M.; Robeznieks, A., 2013:
Prostate treatments in play. Proton-beam therapy fails to deliver better care

Alaña, L.; Sesé, M.; Cánovas, Vónica.; Punyal, Y.; Fernández, Y.; Abasolo, I.; de Torres, Iés.; Ruiz, C.; Espinosa, Lís.; Bigas, A.; Y Cajal, S.Ramón.; Fernández, P.L.; Serras, F.; Corominas, M.; Thomson, T.M.; Paciucci, R., 2014:
Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression

Quigley, M.M.; Mate, T.P.; Sylvester, J.E., 2008:
Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses

Yates, C., 2012 :
Prostate tumor cell plasticity: a consequence of the microenvironment

Xu, T.; He, K.; Wang, L.; Goldkorn, A., 2011:
Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference

Srivastava, A.; Price, D.K.; Figg, W.D., 2015:
Prostate tumor development and androgen receptor function alterations in a new mouse model with ERG overexpression and PTEN inactivation

Kelavkar, U.P.; Hutzley, J.; McHugh, K.; Allen, K.G.D.; Parwani, A., 2009:
Prostate tumor growth can be modulated by dietarily targeting the 15-lipoxygenase-1 and cyclooxygenase-2 enzymes

Moiola, C.P.; D.L.ca, P.; Zalazar, F.; Cotignola, J.; Rodríguez-Seguí, S.A.; Gardner, K.; Meiss, R.; Vallecorsa, P.; Pignataro, O.; Mazza, O.; Vazquez, E.S.; D.S.ervi, A., 2015:
Prostate tumor growth is impaired by CtBP1 depletion in high-fat diet-fed mice

Jiménez Parra, Jé.D.; Guarch Troyas, R.; Alvarez Bandres, S.; Ripa Saldías, L.; Cebrian Lostal, Jé.Luis., 2010:
Prostate tumor of Müllerian origin

Mazaheri, Y.; Hricak, H.; Fine, S.W.; Akin, O.; Shukla-Dave, A.; Ishill, N.M.; Moskowitz, C.S.; Grater, J.E.; Reuter, V.E.; Zakian, K.L.; Touijer, K.A.; Koutcher, J.A., 2009:
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume

Lundholm, M.; Schröder, M.; Nagaeva, O.; Baranov, V.; Widmark, A.; Mincheva-Nilsson, L.; Wikström, P., 2015:
Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion

Hong, M.K.H.; Namdarian, B.; Corcoran, N.M.; Pedersen, J.; Murphy, D.G.; Peters, J.S.; Harewood, L.; Sapre, N.; Rzetelski-West, K.; Costello, A.J.; Hovens, C.M., 2011:
Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup

L.N.bin, J.; Orczyk, Cément.; Deng, F-Ming.; Melamed, J.; Rusinek, H.; Taneja, S.S.; Rosenkrantz, A.B., 2015:
Prostate tumour volumes: evaluation of the agreement between magnetic resonance imaging and histology using novel co-registration software

Liska, J.; Repiska, V.; Galbavy, S.; Polak, S.; Varga, I.; Blasko, M.; Macejova, D.; Brtko, J., 2007:
Prostate tumours--histological classification and molecular aspects of prostate tumorigenesis

Haroon, S.; Uddin, N., 2014:
Prostate type epithelial polyps of urogenital tract: a series of 3 cases and literature review

Chiang, P-Hui.; Chen, C-Hsu., 2010:
Prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-w high-intensity diode laser

Yashi, M.; Mizuno, T.; Yuki, H.; Masuda, A.; Kambara, T.; Betsunoh, H.; Abe, H.; Fukabori, Y.; Muraishi, O.; Suzuki, K.; Nakazato, Y.; Kamai, T., 2014:
Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy

Selice, R.; Caretta, N.; D.M.mbro, A.; Torino, M.; Palego, P.; Ferlin, A.; Foresta, C., 2013:
Prostate volume and growth during testosterone replacement therapy is related to visceral obesity in Klinefelter syndrome

Sooriakumaran, P.; Srivastava, A.; Bhagat, D.; John, M.; Grover, S.; El-Douaihy, Y.; Rajan, S.; Leung, R.; Tewari, A., 2011:
Prostate volume and its correlation with histopathological outcomes in prostate cancer

Yadav, R.; Tu, J.J.; Jhaveri, J.; Leung, R.A.; Rao, S.; Tewari, A.K., 2009:
Prostate volume and the incidence of extraprostatic extension: is there a relation?

Chira, C.; Delouya, G.; Larrivée, S.; Carrier, J-Francois.; Taussky, D., 2014:
Prostate volume changes during permanent seed brachytherapy: an analysis of intra-operative variations, predictive factors and clinical implication

Loeb, S.; Kettermann, A.; Carter, H.Ballentine.; Ferrucci, L.; Metter, E.Jeffrey.; Walsh, P.C., 2009:
Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging

Qu, X.; Huang, Z.; Meng, X.; Zhang, X.; Dong, L.; Zhao, X., 2014:
Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients

Yang, S.Shei-Dei.; Hsieh, C-Hsing.; Chiang, I-Ni.; Lin, C-Da.; Chang, S-Jen., 2013:
Prostate volume did not affect voiding function improvements in diode laser enucleation of the prostate

Cho, I-Chang.; Kwon, W-An.; Kim, J.Eun.; Joung, J.Young.; Seo, H.Kyung.; Chung, J.; Park, W.Seo.; Lee, K.Hyun., 2011:
Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens

Pannek, Jürgen.; Bartel, P.; Göcking, K.; Frotzler, A., 2013:
Prostate volume in male patients with spinal cord injury: a question of nerves?

Porcaro, A.B.; Novella, G.; Molinari, A.; Terrin, A.; Minja, A.; D.M.rco, V.; Martignoni, G.; Brunelli, M.; Cerruto, M.A.; Curti, P.; Cavalleri, S.; Artibani, W., 2016:
Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer

Kim, S.Bin.; Cho, I-Chang.; Min, S.Ki., 2015:
Prostate volume measurement by transrectal ultrasonography: comparison of height obtained by use of transaxial and midsagittal scanning

Karademir, I.; Shen, D.; Peng, Y.; Liao, S.; Jiang, Y.; Yousuf, A.; Karczmar, G.; Sammet, S.; Wang, S.; Medved, M.; Antic, T.; Eggener, S.; Oto, A., 2014:
Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer

Dianat, S.Saeid.; Rancier Ruiz, R.M.; Bonekamp, D.; Carter, H.Ballentine.; Macura, K.J., 2013:
Prostate volumetric assessment by magnetic resonance imaging and transrectal ultrasound: impact of variation in calculated prostate-specific antigen density on patient eligibility for active surveillance program

Chow, J.C.L.; Jiang, R., 2013:
Prostate volumetric-modulated arc therapy: dosimetry and radiobiological model variation between the single-arc and double-arc technique

Ahlering, T.E.; Kaplan, A.G.; Yee, D.S.; Skarecky, D.W., 2008:
Prostate weight and early potency in robot-assisted radical prostatectomy

Hong, M.K.H.; Yao, H.H.I.; Rzetelski-West, K.; Namdarian, B.; Pedersen, J.; Peters, J.S.; Hovens, C.M.; Corcoran, N.M., 2012:
Prostate weight is the preferred measure of prostate size in radical prostatectomy cohorts

Msezane, L.P.; Gofrit, O.N.; Lin, S.; Shalhav, A.L.; Zagaja, G.P.; Zorn, K.C., 2007:
Prostate weight: an independent predictor for positive surgical margins during robotic-assisted laparoscopic radical prostatectomy

Kuehn, B.M., 2012:
Prostate, baldness drugs linked to sexual dysfunction

Nau, J-Yves., 2012:
Prostate, cancer and lost patients

Makarov, D.V.; Partin, A.W., 2007:
Prostate-Cancer Risk Stratification via Early PSA Testing

Chang, J-Seok.; Choi, H.; Chang, Y-Seop.; Kim, J-Bum.; Oh, M.Mi.; Moon, D.Geon.; Bae, J.Hyun.; Cheon, J., 2012:
Prostate-Specific Antigen Density as a Powerful Predictor of Extracapsular Extension and Positive Surgical Margin in Radical Prostatectomy Patients with Prostate-Specific Antigen Levels of Less than 10 ng/ml

MacDonald, J.A.; Moffat, L.D.; Al-Ghabkari, A.; Sutherland, C.; Walsh, M.P., 2013:
Prostate-apoptosis response-4 phosphorylation in vascular smooth muscle

Zeng, Y.; Gao, D.; Kim, J.J.; Shiraishi, T.; Terada, N.; Kakehi, Y.; Kong, C.; Getzenberg, R.H.; Kulkarni, P., 2013:
Prostate-associated gene 4 (PAGE4) protects cells against stress by elevating p21 and suppressing reactive oxygen species production

D'Amico, A.V., 2012:
Prostate-cancer mortality after PSA screening

Autier, P.; Boniol, M.; Perrin, P., 2012:
Prostate-cancer mortality after PSA screening

Wolf, A.M.D., 2012:
Prostate-cancer mortality after PSA screening

Schröder, F.H.; Hugosson, J.; Roobol, M.J.; Tammela, T.L.J.; Ciatto, S.; Nelen, V.; Kwiatkowski, M.; Lujan, M.; Lilja, H.; Zappa, M.; Denis, L.J.; Recker, F.; Páez, A.; Määttänen, L.; Bangma, C.H.; Aus, G.; Carlsson, S.; Villers, A.; Rebillard, X.; van der Kwast, T.; Kujala, P.M.; Blijenberg, B.G.; Stenman, U-Hakan.; Huber, A.; Taari, K.; Hakama, M.; Moss, S.M.; de Koning, H.J.; Auvinen, A.; Kirkels, W.J.; Rietbergen, J.B.W.; van der Cruijsen, I.W.; Raaijmakers, R.; de Vries, S.H.; Roemelin, 2012:
Prostate-cancer mortality at 11 years of follow-up

Collin, S.M.; Martin, R.M.; Metcalfe, C.; Gunnell, D.; Albertsen, P.C.; Neal, D.; Hamdy, F.; Stephens, P.; Lane, J.Athene.; Moore, R.; Donovan, J., 2008:
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study

Preston, S.H., 2009:
Prostate-cancer screening

Patrick, A., 2010:
Prostate-cancer screening in an Afro-Caribbean population: the Tobago Prostate Cancer Screening Study

Robinson, K.P.; Chan, J.J., 2018:
Colchicine in dermatology: A review

Schapira, D.; Jarrett, A., 1993:
Prostate-cancer surveillance - a cost-effective strategy

Saylor, P.J.; Fogerty, A.E., 2010:
Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?

Liu, J.; Kopečková, P.; Pan, H.; Sima, M.; Bühler, P.; Wolf, P.; Elsässer-Beile, U.; Kopeček, Jřich., 2012:
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates

Ghadersohi, A.; Sharma, S.; Zhang, S.; Azrak, R.G.; Wilding, G.E.; Manjili, M.H.; Li, F., 2011:
Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer

Proutski, I.; Stevenson, L.; Allen, W.L.; McCulla, A.; Boyer, J.; McLean, E.G.; Longley, D.B.; Johnston, P.G., 2010:
Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells

Wojtala, R.L.; Tavares, I.A.; Morton, P.E.; Valderrama, F.; Thomas, N.Shaun.B.; Morris, J.D.H., 2011:
Prostate-derived sterile 20-like kinases (PSKs/TAOKs) are activated in mitosis and contribute to mitotic cell rounding and spindle positioning

Tavares, I.A.; Touma, D.; Lynham, S.; Troakes, C.; Schober, M.; Causevic, M.; Garg, R.; Noble, W.; Killick, R.; Bodi, I.; Hanger, D.P.; Morris, J.D.H., 2013:
Prostate-derived sterile 20-like kinases (PSKs/TAOKs) phosphorylate tau protein and are activated in tangle-bearing neurons in Alzheimer disease

Zilli, T.; Benz, E.; Miralbell, R., 2014:
Prostate-rectum spacers: optimization of prostate cancer irradiation

Yao, M.; Taylor, R.A.; Richards, M.G.; Sved, P.; Wong, J.; Eisinger, D.; Xie, C.; Salomon, R.; Risbridger, G.P.; Dong, Q., 2010:
Prostate-regenerating capacity of cultured human adult prostate epithelial cells

Li, X.; Liu, Y-Hong.; Lee, S-Jin.; Gardner, T.A.; Jeng, M-Huey.; Kao, C., 2008:
Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy

Ouzaïd, I.; Cussenot, O.; Rouprêt, M., 2010:
Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end

Stein, J.P.; Hautmann, R.E.; Penson, D.; Skinner, D.G., 2008:
Prostate-sparing cystectomy: a review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer

Kefer, J.C.; Cherullo, E.E.; Jones, J.Stephen.; Gong, M.C.; Campbell, S.C., 2007:
Prostate-sparing cystectomy: has Pandora's box been opened?

de Vries, R.R.; Nieuwenhuijzen, J.A.; van Tinteren, H.; Oddens, J.R.; Visser, O.; van der Poel, H.G.; Bex, A.; Meinhardt, W.; Horenblas, S., 2009:
Prostate-sparing cystectomy: long-term oncological results

Macek, P.; Sanchez-Salas, R.; Rozet, F.; Barret, E.; Galiano, M.; Hanus, T.; Cathelineau, X., 2014:
Prostate-sparing radical cystectomy for selected patients with bladder cancer

Lundon, D.; Loeb, S., 2014:
Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer

Diamandis, E.P., 2008:
Prostate-specific Antigen: Its Usefulness in Clinical Medicine

Leow, C.Ching.; Wang, B-Er.; Ross, J.; Chan, S.M.; Zha, J.; Carano, R.A.D.; Frantz, G.; Shen, M.M.; de Sauvage, F.J.; Gao, W-Qiang., 2009:
Prostate-specific Klf6 inactivation impairs anterior prostate branching morphogenesis through increased activation of the Shh pathway

Satoh, T.; Ishiyama, H.; Matsumoto, K.; Tsumura, H.; Kitano, M.; Hayakawa, K.; Ebara, S.; Nasu, Y.; Kumon, H.; Kanazawa, S.; Miki, K.; Egawa, S.; Aoki, M.; Toya, K.; Yorozu, A.; Nagata, H.; Saito, S.; Baba, S., 2008:
Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis

D'Amico, A.V., 2008:
Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer

Pizent, A.; Colak, B.; Kljaković, Z.; Telisman, S., 2009:
Prostate-specific antigen (PSA) in serum in relation to blood lead concentration and alcohol consumption in men

Williams, S.A.; Xu, Y.; D.M.rzo, A.M.; Isaacs, J.T.; Denmeade, S.R., 2010:
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice

Jansen, F.H.; van Schaik, R.H.N.; Kurstjens, J.; Horninger, W.; Klocker, H.; Bektic, J.; Wildhagen, M.F.; Roobol, M.J.; Bangma, C.H.; Bartsch, G., 2011:
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection

Guazzoni, G.; Nava, L.; Lazzeri, M.; Scattoni, V.; Lughezzani, G.; Maccagnano, C.; Dorigatti, F.; Ceriotti, F.; Pontillo, M.; Bini, V.; Freschi, M.; Montorsi, F.; Rigatti, P., 2011:
Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting

Ng, M.K.; Van As, N.; Thomas, K.; Woode-Amissah, R.; Horwich, A.; Huddart, R.; Khoo, V.; Thompson, A.; Dearnaley, D.; Parker, C., 2008:
Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time

Obertová, Z.; Scott, N.; Brown, C.; Hodgson, F.; Stewart, A.; Holmes, M.; Lawrenson, R., 2015:
Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand

Loeb, S.; Catalona, W.J., 2012:
Prostate-specific antigen (PSA) should drive doing prostate biopsies

Nordström, T.; Aly, M.; Clements, M.S.; Weibull, C.E.; Adolfsson, J.; Grönberg, H., 2013:
Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011

Crawford, E.David.; Moul, J.W.; Rove, K.O.; Pettaway, C.A.; Lamerato, L.E.; Hughes, A., 2011:
Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone

Patanè, S.; Marte, F., 2010:
Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario

Kraus, T.S.; Cohen, C.; Siddiqui, M.T., 2011:
Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

Stephan, C.; Ralla, B.; Jung, K., 2014:
Prostate-specific antigen and other serum and urine markers in prostate cancer

Armstrong, A.J.; Garrett-Mayer, E.; O.Y.ng, Y-Chun.; Carducci, M.A.; Tannock, I.; de Wit, R.; Eisenberger, M., 2007:
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

Wallner, L.P.; Jacobsen, S.J., 2014:
Prostate-specific antigen and prostate cancer mortality: a systematic review

Shahab, A.Anies.; Soebadi, D.M.; Djatisoesanto, W.; Hardjowijoto, S.; Soetojo, S.; Hakim, L., 2013:
Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

Levitt, J.M.; Slawin, K.M., 2008:
Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression

Dusing, R.W.; Peng, W.; Lai, S-Min.; Grado, G.L.; Holzbeierlein, J.M.; Thrasher, J.Brantley.; Hill, J.; Van Veldhuizen, P.J., 2015:
Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence

Poliakovskiĭ, K.A.; Glukhov, A.I.; zezerov, E.G.; Varshavskiĭ, V.A.; Vinarov, A.Z.; Amosov, A.V.; Rapoport, L.M.; Aliaev, I.G.; Severin, E.S.; Zimnik, O.V., 2009:
Prostate-specific antigen and telomerase in prostatic cancers

Walsh, T.; Warner, L.; Macaluso, M.; Frezieres, R.; Snead, M.; Wraxall, B., 2012:
Prostate-specific antigen as a biomarker of condom failure: comparison of three laboratory assays and self-reported condom use problems in a randomized trial of female condom performance

Boccon-Gibod, L., 2007:
Prostate-specific antigen as a diagnostic tool: how useful and reliable is it?

Nanri, M.; Nanri, K.; Fujiyama, C.; Tokuda, Y.; Nakamura, K.; Uozumi, J., 2007:
Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer

Lo, A.C.; Morris, W.James.; Lapointe, V.; Hamm, J.; Keyes, M.; Pickles, T.; McKenzie, M.; Spadinger, I., 2014:
Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival

Patel, N.; Souhami, L.; Mansure, J.João.; Duclos, M.; Aprikian, A.; Faria, S.; David, M.; Cury, F.L., 2014:
Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy

Sheinbein, C.; Teh, B.S.; Mai, W.Y.; Grant, W.; Paulino, A.; Butler, E.Brian., 2010:
Prostate-specific antigen bounce after intensity-modulated radiotherapy for prostate cancer

Zwahlen, D.R.; Smith, R.; Andrianopoulos, N.; Matheson, B.; Royce, P.; Millar, J.L., 2011:
Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis

Mazeron, R.; Bajard, A.; Pommier, P., 2013:
Prostate-specific antigen bounce after permanent seed prostate brachytherapy: a literature review

Caloglu, M.; Ciezki, J., 2010:
Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon

Vu, C.C.; Haas, J.A.; Katz, A.E.; Witten, M.R., 2014:
Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer

Bernstein, M.B.; Ohri, N.; Hodge, J.W.; Garg, M.; Bodner, W.; Kalnicki, S.; Dicker, A.P.; Guha, C., 2014:
Prostate-specific antigen bounce predicts for a favorable prognosis following brachytherapy: a meta-analysis

Coward, R.M.; Simhan, J.; Carson, C.C., 2009:
Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy

Halabi, S.; Armstrong, A.J.; Sartor, O.; de Bono, J.; Kaplan, E.; Lin, C-Yen.; Solomon, N.C.; Small, E.J., 2014:
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

Sutcliffe, S.; Pakpahan, R.; Sokoll, L.J.; Elliott, D.J.; Nevin, R.L.; Cersovsky, S.B.; Walsh, P.C.; Platz, E.A., 2013:
Prostate-specific antigen concentration in young men: new estimates and review of the literature

Saito, S., 2007:
Prostate-specific antigen cut-off point of 2.5 ng/mL and increasing the number of prostate biopsies results in the detection of curable prostate cancer even in Japanese population

Kabarriti, R.; Ohri, N.; Hannan, R.; Tishbi, N.; Baliga, S.; McGovern, K.P.; Mourad, W.F.; Ghavamian, R.; Kalnicki, S.; Guha, C.; Garg, M.K., 2015:
Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure

Koie, T.; Mitsuzuka, K.; Yoneyama, T.; Narita, S.; Kawamura, S.; Kaiho, Y.; Tsuchiya, N.; Tochigi, T.; Habuchi, T.; Arai, Y.; Ohyama, C.; Yoneyama, T.; Tobisawa, Y., 2015:
Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy

Ha, Y-Sok.; Yu, J.; Salmasi, A.Hassanzadeh.; Patel, N.; Parihar, J.; Singer, E.A.; Kim, J.Hyun.; Kwon, T.Gyun.; Kim, W-Jae.; Kim, I.Yi., 2014:
Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance

Kim, J.Heon.; Doo, S.Whan.; Yang, W.Jae.; Song, Y.Seob.; Kwon, S-Sun., 2013:
Prostate-specific antigen density: a better index of obesity-related PSA decrease in ostensibly healthy Korean men with a PSA <3.0 ng/mL

Liu, S.; Zhang, X.; Wu, Y.; Tu, Y.; He, L., 2008:
Prostate-specific antigen detection by using a reusable amperometric immunosensor based on reversible binding and leasing of HRP-anti-PSA from phenylboronic acid modified electrode

Nowroozi, M.Reza.; Zeighami, S.; Ayati, M.; Jamshidian, H.; Ranjbaran, A.Reza.; Moradi, A.; Afsar, F., 2009:
Prostate-specific antigen doubling time as a predictor of Gleason grade in prostate cancer

Thomsen, F.Birkebaek.; Christensen, I.Jarle.; Brasso, K.; Røder, M.Andreas.; Iversen, P., 2014:
Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer

Oudard, S.; Banu, E.; Scotte, F.; Banu, A.; Medioni, J.; Beuzeboc, P.; Joly, F.; Ferrero, J-M.; Goldwasser, F.; Andrieu, J-M., 2007:
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients

Perlmutter, M.A.; Lepor, H., 2008:
Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy

Bartoletti, R., 2011:
Prostate-specific antigen dynamics and prostate cancer diagnosis

Lebdai, S.; Prezelin, Y.; Pereira, H.; Bruyere, F., 2014:
Prostate-specific antigen evolution after photoselective vaporization of the prostate

Angelergues, A.; Maillet, D.; Fléchon, A.; Ozgüroglu, M.; Mercier, F.; Guillot, A.; L.M.ulec, S.; Gravis, G.; Beuzeboc, P.; Massard, C.; Fizazi, K.; de L.M.tte Rouge, T.; Delanoy, N.; Elaidi, R-Thierry.; Oudard, Séphane., 2014:
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Sella, A.; Sternberg, C.N.; Skoneczna, I.; Kovel, S., 2008:
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer

Lippi, G.; Mattiuzzi, C.; Cervellin, G., 2013:
Prostate-specific antigen for prostate cancer screening: a different strategy should be planned

Graefen, M.; Fröhner, M.; Wirth, M., 2011 :
Prostate-specific antigen for treatment monitoring

Mohajeri, A.; Zarghami, N.; Pourhasan Moghadam, M.; Alani, B.; Montazeri, V.; Baiat, A.; Fekhrjou, A., 2012:
Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors

Colloca, G.; Venturino, A.; Addamo, G.; Ratti, R.; Coccorullo, Z.; Caltabiano, G.; Viale, G.; Guarneri, D., 2014:
Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: a monoinstitutional experience

Soga, N.; Onishi, T.; Arima, K.; Sugimura, Y., 2007:
Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy

Malik, R.; Jani, A.B.; Liauw, S.L., 2011:
Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer

Wang, X.; Zhao, M.; Nolte, D.D., 2008:
Prostate-specific antigen immunoassays on the BioCD

Poh, B.Hoon.; Jayaram, G.; Sthaneshwar, P.; Yip, C.Har., 2009:
Prostate-specific antigen in breast disease

Biswas, T.; Datta, A.; Sen, P., 2012:
Prostate-specific antigen in females: A new tool?

Papava, V.L.; Kochiashvili, D.K.; Chovelidze, S.G.; Khardzeishvili, O.M., 2007:
Prostate-specific antigen in serum and prostate epithelium in benign prostatic hyperplasia

Orphanos, G.; Ioannidis, G.; Michael, M.; Kitrou, G., 2008 :
Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease

Thompson, I.M.; Ankerst, D.P., 2007:
Prostate-specific antigen in the early detection of prostate cancer

Radowicki, Sław.; Kunicki, Mł.; Bandurska-Stankiewicz, E., 2007:
Prostate-specific antigen in the serum of women with benign breast disease

Bahamondes, L.; Diaz, J.; Marchi, N.Maria.; Castro, S.; Villarroel, M.; Macaluso, M., 2008:
Prostate-specific antigen in vaginal fluid after exposure to known amounts of semen and after condom use: comparison of self-collected and nurse-collected samples

LeBeau, A.M.; Singh, P.; Isaacs, J.T.; Denmeade, S.R., 2009:
Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity

Rice, C.E.; Gallo, M.F.; Hobbs, M.M.; Lynch, C.D.; Norris, A.H.; Davis, J.A.; Fields, K.S.; Ervin, M.; Turner, A.Norris., 2015:
Prostate-specific antigen is unlikely to be a suitable biomarker of semen exposure from recent unprotected receptive anal intercourse in men who have sex with men

Patanè, S.; Marte, F., 2011:
Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going?

Patanè, S., 2011:
Prostate-specific antigen kallikrein and non-ST elevation myocardial infarction

Patanè, S., 2010:
Prostate-specific antigen kallikrein and the heart

Patanè, S.; Marte, F.; Sturiale, M., 2011:
Prostate-specific antigen kallikrein complexes and acute myocardial infarction

Dominguez-Rodriguez, A.; Abreu-Gonzalez, P.; Avanzas, P.; Hernandez-Garcia, C.; Tome, M.Carrillo-Perez.; Lara-Padron, A., 2011:
Prostate-specific antigen kallikrein is not a marker of non-ST elevation acute coronary syndrome

Patanè, S., 2014:
Prostate-specific antigen kallikrein, non-ST elevation myocardial infarction and a new-onset atrial fibrillation in hypertensive patients

Patanè, S.; Marte, F., 2010:
Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system

Pickles, T., 2007:
Prostate-specific antigen kinetics after failure of primary prostate cancer therapy: a valuable prognostic factor

Castellucci, P.; Fuccio, C.; Marzola, M.Cristina.; Al-Nahhas, A.; Rubello, D.; Fanti, S., 2011:
Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer

Saad, F.; Segal, S.; Eastham, J., 2014:
Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid

Ross, A.E.; Loeb, S.; Landis, P.; Partin, A.W.; Epstein, J.I.; Kettermann, A.; Feng, Z.; Carter, H.Ballentine.; Walsh, P.C., 2010:
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program

Pinkawa, M.; Piroth, M.D.; Holy, R.; Fischedick, K.; Schaar, S.; Borchers, H.; Heidenreich, A.; Eble, M.J., 2010:
Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer

van den Bergh, R.C.N.; Roemeling, S.; Roobol, M.J.; Wolters, T.; Schröder, F.H.; Bangma, C.H., 2008 :
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review

Fitzpatrick, J.M.; Banu, E.; Oudard, S., 2009:
Prostate-specific antigen kinetics in localized and advanced prostate cancer

Takechi, H.; Ito, K.; Yamamoto, T.; Miyakubo, M.; Ohi, M.; Suzuki, K., 2008:
Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan

Gacci, M.; Cai, T.; Siena, G.; Minervini, A.; Torshizi, M.Fayaz.; Bartolini, M.; Giannì, G.; Saieva, C.; Ceroti, M.; Detti, B.; Livi, L.; Pupi, A.; Carini, M., 2015:
Prostate-specific antigen kinetics parameters are predictive of positron emission tomography features worsening in patients with biochemical relapse after prostate cancer treatment with radical intent: Results from a longitudinal cohort study

Zhang, L-Min.; Jiang, H-Wen.; Tong, S-Jun.; Zhu, H-Qing.; Liu, J.; Ding, Q., 2014:
Prostate-specific antigen kinetics under androgen deprivation therapy and prostate cancer prognosis

Khalid, K.Eltahir.; Brair, A.Ibrahim.; Elhaj, A.Mohamed.; Ali, K.Eltom., 2011:
Prostate-specific antigen level and risk of bone metastasis in Sudanese patients with prostate cancer

Chia, S-Eng.; Lau, W.Ko.; Cheng, C.; Chin, C.Min.; Tan, J.; Ho, S.Hong., 2007:
Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study

Helzsouer, K.J.; Newby, J.; Comstock, G.W., 2008:
Prostate-specific antigen levels and subsequent prostate cancer: potential for screening

Vyssoulis, G.; Karpanou, E.; Kyvelou, S-Maria.; Vlachopoulos, C.; Tzamou, V.; Stefanadis, C., 2013:
Prostate-specific antigen levels are associated with arterial stiffness in essential hypertensive patients

Camacho, F.M.; López-Elorza, F.; Rodríguez-Rey, E.M.; Coronel-Pérez, I.M., 2008:
Prostate-specific antigen levels as hyperandrogenism marker in women

Patanè, S.; Marte, F., 2013:
Prostate-specific antigen levels in hypertensive patients suffering from a non-ST elevation myocardial infarction or a new-onset atrial fibrillation

Litchfield, M.J.; Cumming, R.G.; Smith, D.P.; Naganathan, V.; L.C.uteur, D.G.; Waite, L.M.; Blyth, F.M.; Handelsman, D.J., 2012:
Prostate-specific antigen levels in men aged 70 years and over: findings from the CHAMP study

Bidgoli, S.Arbabi.; Jabari, N.; Zavarhei, M.Djamali., 2014:
Prostate-specific antigen levels in relation to background factors: are there links to endocrine disrupting chemicals and AhR expression?

Singer, E.A.; Palapattu, G.S.; van Wijngaarden, E., 2008:
Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey

Parekh, D.J.; Ankerst, D.P.; Thompson, I.M., 2007:
Prostate-specific antigen levels, prostate-specific antigen kinetics, and prostate cancer prognosis: a tocsin calling for prospective studies

Pinzani, P.; Lind, K.; Malentacchi, F.; Nesi, G.; Salvianti, F.; Villari, D.; Kubista, M.; Pazzagli, M.; Orlando, C., 2008:
Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction

Park, T.Yong.; Chae, J.Yun.; Kim, J.Wook.; Kim, J.Wook.; Oh, M.Mi.; Yoon, C.Yong.; Moon, D.Geon., 2013:
Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of korean men with biopsy-proven benign prostatic hyperplasia

Nariţa, D.; Anghel, A.; Motoc, M., 2008:
Prostate-specific antigen may serve as a pathological predictor in breast cancer

Inoue, H.; Nishimura, K.; Yamaguchi, S.; Nonomura, N.; Hara, T., 2015:
Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence

Hong, S.Young.; Cho, D.Sung.; Kim, S.Il.; Ahn, H.Soo.; Kim, S.Joong., 2012:
Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer

Hussain, M.; Goldman, B.; Tangen, C.; Higano, C.S.; Petrylak, D.P.; Wilding, G.; Akdas, A.M.; Small, E.J.; Donnelly, B.J.; Sundram, S.Kanaga.; Burch, P.A.; Dipaola, R.S.; Crawford, E.David., 2009:
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

Prada, P.J.; Juan, Gán.; González-Suárez, H.; Fernández, Jé.; Jimenez, I.; Amón, Jé.; Cepeda, M., 2010:
Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants

Korytko, T.P.; Lowe, G.J.; Jimenez, R.E.; Pohar, K.S.; Martin, D.D., 2013:
Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma

Cury, F.L.; Hunt, D.; Roach, M.; Shipley, W.; Gore, E.; Hsu, I-Chow.; Krisch, R.E.; Seider, M.J.; Sandler, H.; Lawton, C., 2013:
Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413

Song, G.; Lee, C.; You, D.; Jeong, I.Gab.; Hong, J.Hyuk.; Ahn, H.; Kim, C-Soo., 2013:
Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice

Kijima, T.; Fujii, Y.; Yokoyama, M.; Ishioka, J.; Matsuoka, Y.; Numao, N.; Saito, K.; Koga, F.; Masuda, H.; Kawakami, S.; Kihara, K., 2012:
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer

Biehn, J., 2012:
Prostate-specific antigen screening

Scales, C.D.; Antonelli, J.; Curtis, L.H.; Schulman, K.A.; Moul, J.W., 2008:
Prostate-specific antigen screening among young men in the United States

Roobol, M.J.; Bangma, C.H.; Loeb, S., 2013:
Prostate-specific antigen screening can be beneficial to younger and at-risk men

Scosyrev, E.; Wu, G.; Mohile, S.; Messing, E.M., 2013:
Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time

Black, A.; Berg, C.D., 2012:
Prostate-specific antigen screening for prostate cancer in older men in the United States of America

Hayes, J.H.; Barry, M.J.; Kantoff, P.W.; Stahl, J.E., 2007:
Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective

Labrie, F., 2014:
Prostate-specific antigen screening for prostate cancer: why so much controversy?

Wilt, T.J.; Scardino, P.T.; Carlsson, S.V.; Basch, E., 2014:
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence

Wever, E.M.; Draisma, G.; Heijnsdijk, E.A.M.; Roobol, M.J.; Boer, R.; Otto, S.J.; de Koning, H.J., 2010:
Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam

Kawada, T.; Muto, K.; Kanai, T.; Kuratomi, Y., 2010:
Prostate-specific antigen screening of workers under the age of 40 in Japan

Haines, I.E.; Gabor Miklos, G.L., 2013:
Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection

Sountoulides, P.; Moutzouris, G., 2015:
Prostate-specific antigen screening, why have the guidelines changed?

Robinson, J.G.; Hodges, E.A.; Davison, J., 2016:
Prostate-specific antigen screening: a critical review of current research and guidelines

Linn, M.Morse.; Ball, R.A.; Maradiegue, A., 2008:
Prostate-specific antigen screening: friend or foe?

Loeb, S.; Catalona, W.J., 2010:
Prostate-specific antigen screening: pro

Davis, N.F.; McGuire, B.B.; Flood, H.D., 2010:
Prostate-specific antigen self-testing among British Association of Urological Surgeons (BAUS) consultant urologists

Beriwal, S.; Smith, R.P.; Houser, C.; Benoit, R.M., 2013:
Prostate-specific antigen spikes with ¹³¹Cs brachytherapy. Is there a difference with other radioisotopes?

Yeboa, D.Nana.; Guzzo, T.; Mitra, N.; Christodouleas, J.P.; Haas, N.B.; Vapiwala, N.; Armstrong, K.; Bekelman, J.E., 2011 :
Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment

Nam, R.K.; Oliver, T.K.; Vickers, A.J.; Thompson, I.; Kantoff, P.W.; Parnes, H.L.; Loblaw, A.; Roth, B.J.; Williams, J.; Temin, S.; Basch, E., 2013:
Prostate-specific antigen test for prostate cancer screening: American Society of Clinical Oncology provisional clinical opinion

Lawrentschuk, N.; Daljeet, N.; Ma, C.; Hersey, K.; Zlotta, A.; Fleshner, N., 2011:
Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns

Ross, L.E.; Meade, S-Ann.; Powe, B.D.; Howard, D.L., 2009:
Prostate-specific antigen test use and digital rectal examinations among African-American men, 2002-2006

Haythorn, M.R.; Ablin, R.J., 2012:
Prostate-specific antigen testing across the spectrum of prostate cancer

Hudson, S.V.; Ohman-Strickland, P.; Ferrante, J.M.; Lu-Yao, G.; Orzano, A.John.; Crabtree, B.F., 2009:
Prostate-specific antigen testing among the elderly in community-based family medicine practices

Avery, K.N.L.; Metcalfe, C.; Blazeby, J.M.; Lane, J.Athene.; Neal, D.E.; Hamdy, F.C.; Donovan, J.L., 2008:
Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?

Djavan, B.; Eckersberger, E.; Finkelstein, J.; Sadri, H.; Taneja, S.S.; Lepor, H., 2010:
Prostate-specific antigen testing and prostate cancer screening

Schröder, F.H.; Zappa, M., 2012:
Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

Braillon, A., 2014:
Prostate-specific antigen testing in france

Goodwin, J.S.; Tan, A.; Jaramillo, E.; Kuo, Y-Fang., 2013:
Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials

Scosyrev, E.; Wu, G.; Golijanin, D.; Messing, E., 2013:
Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system

Williams, N.; Hughes, L.J.; Turner, E.L.; Donovan, J.L.; Hamdy, F.C.; Neal, D.E.; Martin, R.M.; Metcalfe, C., 2011:
Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities

Squiers, L.B.; Bann, C.M.; Dolina, S.E.; Tzeng, J.; McCormack, L.; Kamerow, D., 2013:
Prostate-specific antigen testing: men's responses to 2012 recommendation against screening

Kell, J.S., 2010:
Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians

Tuppin, P.; Samson, Sène.; Perrin, P.; Ruffion, A.; Millat, B.; Weill, A.; Ricordeau, P.; Allemand, H., 2012:
Prostate-specific antigen use among men without prostate cancer in France (2008-2010)

Zheng, X-Yi.; Zhang, P.; Xie, L-Ping.; You, Q-Han.; Cai, B-Sen.; Qin, J., 2013:
Prostate-specific antigen velocity (PSAV) and PSAV per initial volume (PSAVD) for early detection of prostate cancer in Chinese men

Loeb, S.; Metter, E.Jeffrey.; Kan, D.; Roehl, K.A.; Catalona, W.J., 2012:
Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Thanigasalam, R.; Mancuso, P.; Tsao, K.; Rashid, P., 2010:
Prostate-specific antigen velocity (PSAV): a practical role for PSA?

Tang, P.; Sun, L.; Uhlman, M.A.; Robertson, C.N.; Polascik, T.J.; Moul, J.W., 2011:
Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men

Park, J.J.; Chen, M-Hui.; Loffredo, M.; D'Amico, A.V., 2012:
Prostate-specific antigen velocity before and after elimination of factors that can confound the prostate-specific antigen level

Vickers, A.J.; Wolters, T.; Savage, C.J.; Cronin, A.M.; O'Brien, M.Frank.; Pettersson, K.; Roobol, M.J.; Aus, G.; Scardino, P.T.; Hugosson, J.; Schröder, F.H.; Lilja, H., 2011:
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

Giovacchini, G.; Picchio, M.; Parra, R.G.; Briganti, A.; Gianolli, L.; Montorsi, F.; Messa, C., 2012:
Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy

Vickers, A.J.; Pencina, M.J., 2014:
Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility

Oh, J.Jin.; Hong, S.Kyu.; Lee, J.Keun.; Lee, B.Ki.; Lee, S.; Kwon, O.Sung.; Byun, S-Soo.; Lee, S.Eun., 2013:
Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy

Kuriyama, M., 2011:
Prostate-specific antigen(PSA), PSA-ACT, free PSA and F/T

Jackson, B.R., 2013:
Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?

Thompson, I.M.; Ankerst, D.P.; Tangen, C.M., 2010:
Prostate-specific antigen, risk factors, and prostate cancer: confounders nestled in an enigma

Werny, D.M.; Saraiya, M.; Chen, X.; Platz, E.A., 2007:
Prostate-specific antigen, sexual behavior, and sexually transmitted infections in US men 40-59 years old, 2001-2004: a cross-sectional study

Bratt, O.; Björk, T., 2007:
Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed

Bokhorst, L.P.; Bangma, C.H.; van Leenders, G.J.L.H.; Lous, J.J.; Moss, S.M.; Schröder, F.H.; Roobol, M.J., 2014:
Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

Strope, S.A.; Andriole, G.L., 2012:
Prostate-specific antigen-based risk assessment in younger men

Tang, P.; Sun, L.; Uhlman, M.A.; Robertson, C.N.; Polascik, T.J.; Albala, D.M.; Donatucci, C.F.; Moul, J.W., 2010:
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men

Lippi, G.; Montagnana, M.; Guidi, G.Cesare.; Plebani, M., 2011:
Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?

Ito, K., 2009:
Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives

Carter, H.Ballentine., 2014 :
Prostate-specific antigen-based screening for prostate cancer: the irony of it all

Froehner, M.; Abolmaali, N.; Wirth, M.P., 2013:
Prostate-specific antigen-negative prostate cancer recurrence?

Hammer, A.; Hager, H.; Steiniche, T., 2008:
Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer

Sánchez-Martínez, L.Carlos.; Paredes-Solís, César.Armando.; Hernández-Ordóñez, O.Francisco.; Sánchez-Ruvalcaba, I.Rigel., 2014:
Prostate-specific antigen. The role in the prostate cancer diagnosis

Stovsky, M.; Ponsky, L.; Vourganti, S.; Stuhldreher, P.; Siroky, M.B.; Kipnis, V.; Fedotoff, O.; Mikheeva, L.; Zaslavsky, B.; Chait, A.; Jones, J.Stephen., 2011:
Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples

Mongiat-Artus, P.; Desgrandchamps, F., 2010:
Prostate-specific antigen: Aesop tale?

Thompson, I.M.; Tangen, C.M.; Kristal, A.R., 2008:
Prostate-specific antigen: a misused and maligned prostate cancer biomarker

Anonymous, 2011:
Prostate-specific antigen: a new(ish) study

Payne, H.; Cornford, P., 2012:
Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer

LeBeau, A.M.; Kostova, M.; Craik, C.S.; Denmeade, S.R., 2010:
Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer

Obort, A.S.; Ajadi, M.B.; Akinloye, O., 2013:
Prostate-specific antigen: any successor in sight?

Speakman, M.J., 2008:
Prostate-specific antigen: could it be a useful marker for bladder outlet obstruction?

Thorek, D.L.J.; Evans, M.J.; Carlsson, S.V.; Ulmert, D.; Lilja, H., 2014:
Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles

Mize, G.J.; Wang, W.; Takayama, T.K., 2008:
Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2

Abdel-Hadi, M.; Ismail, Y.; Younis, L., 2017:
Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients

Mlcochová, P.; Barinka, C.; Tykvart, J.; Sácha, P.; Konvalinka, J., 2009:
Prostate-specific membrane antigen and its truncated form PSM'

Ren, H.; Zhang, H.; Wang, X.; Liu, J.; Yuan, Z.; Hao, J., 2014:
Prostate-specific membrane antigen as a marker of pancreatic cancer cells

Wernicke, A.Gabriella.; Edgar, M.A.; Lavi, E.; Liu, H.; Salerno, P.; Bander, N.H.; Gutin, P.H., 2011:
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme

Rajasekaran, S.A.; Christiansen, J.J.; Schmid, I.; Oshima, E.; Ryazantsev, S.; Sakamoto, K.; Weinstein, J.; Rao, N.P.; Rajasekaran, A.K., 2008:
Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability

Zhao, L-Yun.; Mao, X-Peng.; Chao, K-Yuan.; Guo, S-Jie.; Qiu, S-Peng., 2013:
Prostate-specific membrane antigen can promote in vivo osseous metastasis of prostate cancer cells in mice

Haffner, M.C.; Kronberger, I.E.; Ross, J.S.; Sheehan, C.E.; Zitt, M.; Mühlmann, G.; Ofner, D.; Zelger, B.; Ensinger, C.; Yang, X.J.; Geley, S.; Margreiter, R.; Bander, N.H., 2009:
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers

Wernicke, A.Gabriella.; Varma, S.; Greenwood, E.A.; Christos, P.J.; Chao, K.S.Clifford.; Liu, H.; Bander, N.H.; Shin, S.J., 2014:
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers

Mhawech-Fauceglia, P.; Smiraglia, D.J.; Bshara, W.; Andrews, C.; Schwaller, J.; South, S.; Higgs, D.; Lele, S.; Herrmann, F.; Odunsi, K., 2008:
Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma

Kasperzyk, J.L.; Finn, S.P.; Flavin, R.; Fiorentino, M.; Lis, R.; Hendrickson, W.K.; Clinton, S.K.; Sesso, H.D.; Giovannucci, E.L.; Stampfer, M.J.; Loda, M.; Mucci, L.A., 2014:
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer

Liu, C.; Hasegawa, K.; Russell, S.J.; Sadelain, M.; Peng, K-Whye., 2009:
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer

Kularatne, S.A.; Wang, K.; Santhapuram, H-Krishna.R.; Low, P.S., 2009:
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand

Akhtar, N.H.; Pail, O.; Saran, A.; Tyrell, L.; Tagawa, S.T., 2011:
Prostate-specific membrane antigen-based therapeutics

Liu, T.; Wu, L.Y.; Berkman, C.E., 2010 :
Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption

Hasan, Y.; Schoenherr, D.; Martinez, A.A.; Wilson, G.D.; Marples, B., 2010:
Prostate-specific natural health products (dietary supplements) radiosensitize normal prostate cells

Afriyie, D.K.; Asare, G.A.; Bugyei, K.; Asiedu-Gyekye, I.J.; Tackie, R.; Adjei, S., 2015:
Prostate-specific targeting of the aqueous root extract of Croton membranaceus in experimental animals

Kawai, N.; Sato, M.; Hosokawa, S.; Murotani, K.; Sanda, H.; Nakata, K.; Minamiguchi, H.; Nakai, M.; Sonomura, T., 2015:
Prostate-supplying arteriogram created by multidetector-row CT during pelvic arteriography: contribution to the treatment strategy of prostatic artery embolization for prostatic hyperplasia

Yang, J.; Xie, S-Xue.; Huang, Y.; Ling, M.; Liu, J.; Ran, Y.; Wang, Y.; Thrasher, J.Brantley.; Berkland, C.; Li, B., 2013:
Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice

Du, Y-Feng.; Long, Q-Zhi.; Shi, Y.; Liu, X-Gang.; Li, X-Dong.; Zeng, J.; Gong, Y-Guang.; Wang, X-Yang.; He, D-Lin., 2013:
Prostate-targeted mTOR-shRNA inhibit prostate cancer cell growth in human tumor xenografts

Ni, X.; Zhang, Y.; Ribas, J.; Chowdhury, W.H.; Castanares, M.; Zhang, Z.; Laiho, M.; DeWeese, T.L.; Lupold, S.E., 2011:
Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts

Scaggiante, B.; Bonin, S.; Cristiano, L.; Siracusano, S.; Stanta, G.; Dapas, B.; Giansante, C.; Fiotti, N.; Grassi, G., 2008:
Prostate-tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma infection

Ward, A.D.; Crukley, C.; McKenzie, C.A.; Montreuil, J.; Gibson, E.; Romagnoli, C.; Gomez, J.A.; Moussa, M.; Chin, J.; Bauman, G.; Fenster, A., 2012:
Prostate: registration of digital histopathologic images to in vivo MR images acquired by using endorectal receive coil

Traczyk, Z., 1949:
Prostatectomia retropubica, Millin's method

Wheeler, W.I., 1939:
Prostatectomy And Its Post-Operative Management

Alexander, J.F.; Kidd, F.S., 1922:
Prostatectomy In A Case Of Diabetes Insipidus

Irwin, W.K., 1937:
Prostatectomy by the Two-Stage Method

Tillou, X.; Chahwan, C.; L.G.l, S.; Bensadoun, H.; Doerfler, A., 2015:
Prostatectomy for localized prostate cancer to prepare for renal transplantation in end-stage renal disease patients

Cammidge, P.J., 1929:
Prostatectomy in Diabetics

Gorday, A.J., 1948:
Prostatectomy in men over 75

Frater, K., 2010:
Prostatectomy in the 10th decade; report on two cases

Ramirez-Backhaus, M.; Iborra, I.; Gomez-Ferrer, A.; Rubio-Briones, J., 2015:
Prostatectomy pathology findings in an active surveillance population

Brusa, D.; Carletto, S.; Cucchiarale, G.; Gontero, P.; Greco, A.; Simone, M.; Ferrando, U.; Tizzani, A.; Matera, L., 2011:
Prostatectomy restores the maturation competence of blood dendritic cell precursors and reverses the abnormal expansion of regulatory T lymphocytes

Lee, W-Chang.; Lin, Y-Hsiang.; Hou, C-Pang.; Chang, P-Lang.; Chen, C-Lun.; Juang, H-Heng.; Tsui, K-Hung., 2014:
Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males

Eden, C.G., 2014:
Prostatectomy v radiotherapy: possible detrimental effect of hormonal manipulation in patients receiving radiotherapy

Rodriguez Molina, L.F., 2011:
Prostatectomy versus transurethral resection

Markun, S., 2014:
Prostatectomy vs. "watchful waiting" in early prostate cancer

Kisman, M., 2014:
Prostatectomy with Terence Millin's method

Tellman, H.C., 1949:
Prostatectomy, an analysis of Harper Hospital experience during 1946-48

Mangiardi, J.L.; Harris, A., 1948:
Prostatectomy, suprapubic and transurethral

Anonymous, 1965:
Prostatectomy-Early or Late

Armstrong, G.E., 1913:
Prostatectomy-Suspension Of The Bladder

Abe, M.; Kawano, Y.; Kameyama, S., 2012:
Prostatectomy-pros and cons on open surgery/laparoscopic surgery/robot-assisted surgery

Robson, A.W., 1889:
Prostatectomy: A Sequel to the Operation of Suprapubic Lithotomy

Page, W.A., 1935:
Prostatectomy: As Performed By The Late Professor Andrew Fullerton

Macdonald, W.J., 1911:
Prostatectomy: The Suprapubic Route

Mullenix, R.B.; Prentiss, R.J.; Delaval, R.E., 1949:
Prostatectomy; a critical survey of 11 years' experience in private practice

Herman, L.; Carp, J., 1925:
Prostatic Abscess

Joshi, P.; Lele, V., 2013:
Prostatic Adenocarcinoma Masquerading as Generalized lymphadenopathy and Mimicking lymphoma on FDG PET/CT: Diagnosis, Staging, and Evaluation of Therapy Response by FDG PET/CT

Iversen, P.; Borre, M.; Andersen, J.Rye., 2008:
Prostatic Cancer Patient Association PROPA--and information about prostatic cancer

Gardner, S.J.; Cummins, W.T., 1914:
Prostatic Carcinoma in a Youth

Riches, E.W., 1933:
Prostatic Ducts shown in a Cystogram

Walker, K., 1938:
Prostatic Enlargement and its Treatment

Barling, G., 1904:
Prostatic Enlargement and its Treatment by Freyer's Method